Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2'-deoxy-GTP
?
-
effective substrate
-
-
?
2'-O-(N-methylanthraniloyl) guanosine 5'-triphosphate
?
-
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
ATP
adenosine cyclic 3'-5'monophosphate + diphosphate
-
-
-
?
CTP
3',5'-cyclic CMP + diphosphate
-
-
-
-
?
GTP
3',5'-cGMP + diphosphate
GTP
3',5'-cyclic GMP + diphosphate
GTP
3',5'-cyclic-GMP + diphosphate
guanosine 5'-beta,gamma-methylene triphosphate
?
-
-
-
-
?
guanosine-5'-[alpha,beta-methylene]triphosphate
?
-
-
-
-
?
guanyl-(beta,gamma-methylene)-diphosphate
?
-
-
-
?
guanyl-imidodiphosphate
?
-
-
-
?
UTP
3',5'-cyclic UMP + diphosphate
additional information
?
-
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
-
?
GTP
3',5'-cGMP + diphosphate
-
-
-
?
GTP
3',5'-cGMP + diphosphate
-
-
-
-
?
GTP
3',5'-cGMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP in form of MnGTP2-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
prefered substrate
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP in form of MnGTP2-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the receptor membrane-bound guanylate cyclase in the sperm tail triggers sperm chemotaxis, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the receptor membrane-bound guanylate cyclase in the sperm tail triggers sperm chemotaxis, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
converts GTP into cGMP in many cell types upon green light stimulation whereas it is totally inactive in the dark
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
membrane embedded protein converts GTP into cGMP in many cell types upon green light stimulation whereas it is totally inactive in the dark. In contrast to membrane embedded protein, for both purified enzyme a significant dark activity is detected and the cGMP production increases linearly with substrate concentration
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
664860, 665511, 666248, 679399, 680671, 681631, 684348, 690841, 691656, 692446, 693082, 693256, 693267, 694270, 694411 -
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
ir
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
cGMP is involved in transmitting the NO activating signals to a variety of downstream effectors such as cyclicnucleotide-gated channels, protein kinases, and phosphodiesterases
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the guanylyl cyclase messenger system is potentially responsive to hormones/neurotranmitters that may control the degree of relaxation in this vascular tissue
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC produces cGMP, a second messenger required for normal vascular smooth muscle cell, VSMC, relaxation. Activating NADPH oxidase in bovine aortic VSMC increases ROS levels and induces oxidative posttranslational modification of Cys122, a beta1-subunit cysteinyl residue of the guanylate cyclase leading to its inhibition
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme is involved in regualtion of artery contaction, enzyme activation by NO leads to increased pulmonary artery relaxation
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the retinal isozyme retGC-1 influences transducin movement, not through its cyclase activity, but through direct interaction with Galphat protein, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP in form of MgGTP2-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP in form of MnGTP2-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
regulation of intracellular cGMP concentration is essential for normal thermotaxis
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
soluble guanylate cyclase is the mammalian receptor for nitric oxide
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the enzyme acts as a receptor for the molt-inhibiting hormone
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the receptor guanylyl cyclase acts as a molt-inhibiting hormone receptor and is a functional link to ecdysteroidogenesis, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the enzyme produces cGMP in response to green light with a light to dark activity ratio above 1000. After light excitation the putative signaling state forms. The membrane embedded protein converts GTP into cGMP in many cell types upon green light stimulation whereas it is totally inactive in the dark
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the membrane embedded protein converts GTP into cGMP in many cell types upon green light stimulation whereas it is totally inactive in the dark. In contrast to membrane embedded protein, for both purified enzyme a significant dark activity is detected and the cGMP production increases linearly with substrate concentration
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the enzyme produces cGMP in response to green light with a light to dark activity ratio above 1000. After light excitation the putative signaling state forms. The membrane embedded protein converts GTP into cGMP in many cell types upon green light stimulation whereas it is totally inactive in the dark
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the membrane embedded protein converts GTP into cGMP in many cell types upon green light stimulation whereas it is totally inactive in the dark. In contrast to membrane embedded protein, for both purified enzyme a significant dark activity is detected and the cGMP production increases linearly with substrate concentration
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
mechanism of NO stimulation of cGMP production in airway hyperreactivity pathogenesis evoked by toluene inhalation, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
NO is a major signaling molecule in the gastrointestinal tract, and released NO inhibits muscular contraction. The actions of NO are mediated by stimulation of NO-sensitive sGC and a subsequent increase in cGMP concentration
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme has a role in neuronal degeneration
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
isozyme Gyc-89Da in neurons is necessary early in adult development to prevent eclosion, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
isozyme Gyc-89Db in neurons is necessary early in adult development to prevent eclosion, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
678971, 679399, 681867, 690679, 691340, 691543, 691656, 691727, 692204, 692206, 692407, 692545, 692546, 692548 -
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
692585, 692704, 692929, 693087, 693102, 693364, 693365, 693784, 693894, 694121, 694977, 729139, 730028, 730957 -
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
guanylyl cyclase receptors synthesize the second-messenger cyclic GMP
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
in the heart exists a coupled multienzymatic system for selective regulation of indirect, sGC-dependent versus direct, sGC-independent NO- and redox-related modulation of voltage-gated ion channel function in different myocyte types, mechanisms, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
nitric oxide and carbon monoxide are modulators of neurotransmission in cardiac ganglia and in neural control of the adult human heart
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC contributes to the pathology of pulmonary arterial hypertension, its stimulation reverses right heart hypertrophy and structural lung vascular remodelling, hemodynamics and vascular remodelling in lung explants, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC is a receptor for nitric oxide generating cGMP
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
soluble guanylyl cyclase is a key protein in the NO/cGMP signaling pathway
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
soluble guanylyl cyclase is the principal receptor for NO and plays a ubiquitous role in regulating cellular function, sGC governs smooth muscle tone and growth, vascular permeability, leukocyte flux, and platelet aggregation. Aberrant NO-sGC signaling is linked to diseases including hypertension, atherosclerosis, and stroke
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme and cGMP-pathway are involved in NO-mediated cell migration
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme is important in regulation of cardiaovascular functions and vision in humans, allosteric regulation, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the membrane guanylate cyclase is part of a transduction machinery involving the guanylate cyclae, the guanylate cyclase activating protein type 1, S100B, and neurocalcin delta, mechanism, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the NO-independent, heme-dependent soluble guanylate cyclase acts as an NO receptor
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the retinal isozyme retGC-1 influences transducin movement, not through its cyclase activity, but through direct interaction with Galphat protein, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
von Willebrand factor/ristocetin-mediated activation of the sGC/cGMP signaling pathway may contribute to feedback platelet inhibition, regulation mechanisms, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
GTP in form of MgGTP2-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the soluble guanylyl cyclase is the major receptor for NO and contributes to prolonged depolarization of the membrane potential in cerebral giant cells, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
679514, 690355, 690364, 690367, 690841, 691340, 691401, 691542, 691656, 691926, 692083, 692193, 692204, 692547, 692548, 692584, 693152, 693769, 693776, 693821, 693894, 694141, 694347, 694349, 694915 -
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
atrial natriuretic factor receptor guanylate cyclase GC-A is the receptor of the atrial natriuretic factor and the type B natriuretic peptide, overview
cyclic GMP is a second messenger in controlling blood pressure, cardiac vasculature, and fluid secretion
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GC-A acts as receptor for atrial natriuretic peptide that regulates arterial blood pressure and volume, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
guanylyl cyclase receptors synthesize the second-messenger cyclic GMP
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
isozyme GC-A is a common receptor for atrial and brain natriuretic peptide
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
membrane forms of guanylyl cyclase serve as cell-surface receptors that synthesize the second messenger cGMP, which mediates diverse cellular processes. GC-G plays a role in mediating injury, GC-G may act as an early signaling molecule that promotes apoptotic and inflammatory responses in I/R-induced acute renal injury
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
NO receptor isozymes NO-GC1 and NO-GC2 are required for long term potentiation in smooth muscle relaxation, they mediate vasorelaxation and platelet-inhibition of nitric oxide being the only NO receptor of the signalling pathway
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
NO-GC plays a role in neuropathic pain. cGMP produced by NO-GC may activate signaling pathways different from cGMP-dependent protein kinase I, cGKI, during spinal nociceptive processing, whereas cGKI can be activated by natriuretic peptide receptor-B dependent cGMP production, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
role of sGCalpha1beta1 in nitrergic regulation of jejunal smooth muscle activity in male and female mice, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC contributes to the pathology of pulmonary arterial hypertension, its stimulation reverses right heart hypertrophy and structural lung vascular remodelling, hemodynamics and vascular remodelling in a mouse lung model, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice, enzyme inhibition in lung increases the filtration coefficient, regulation, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme is involved in vasorelaxation, NO acts as a signalling molecule regulating sGC expression in a negative feedback loop, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the homodimeric transmembrane guanylyl cyclase-A receptor produces cytoplasmic cyclic GMP from GTP on binding its extracellular ligands, atrial and B-type natriuretic peptides, which modulate blood pressure and volume through the stimulation of cyclic GMP production by their guanylyl cyclase-A receptor, overview. Alternative splicing can regulate endogenous ANP/GC-A signaling, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the regulation of arterial vasodilatory and cardiac beta-adrenergic reserve by phosphodiesterase type 5-I targets cGMP from soluble GC stimulation
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the retina-specific guanylyl cyclases, retGC1 and retGC2 support synthesis of cGMP in photoreceptors
cyclic GMP serves as the second messenger in visual transduction, linking photon absorption by rhodopsin to the activity of ion channels
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the retinal isozyme retGC-1 influences transducin movement, not through its cyclase activity, but through direct interaction with Galphat protein, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the soluble guanylate cyclase isoforms alpha1beta1 and alpha2beta1 are involved in the relaxation of distal colon by exogenous NO and by NANC nerve stimulation, mechanism, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
von Willebrand factor/ristocetin-mediated activation of the sGC/cGMP signaling pathway may contribute to feedback platelet inhibition, regulation mechanisms, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP in form of MgGTP2-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice, enzyme inhibition in lung increases the filtration coefficient, regulation, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme is involved in vasorelaxation, NO acts as a signalling molecule regulating sGC expression in a negative feedback loop, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
cGMP levels in response to relaxant agonists are regulated in gastrointestinal smooth muscle by activation of phosphodiesterase 5 and inhibition of soluble guanylyl cyclase by c-Src-dependent phosphorylation in a feedback mechanism via the cGMP-dependent protein kinase, mechanism for attenuation of the NO/sGC/cGMP signal by Gi-coupled contractile agonists, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme is involved in vasorelaxation, NO acts as a signalling molecule regulating sGC expression in a negative feedback loop, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the receptor membrane-bound guanylate cyclase in the sperm tail triggers sperm chemotaxis, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
677413, 677482, 679399, 679514, 681091, 682935, 690349, 690358, 690658, 690669, 690947, 691072, 691541, 691656, 691659, 692204, 692446, 693272, 693812, 694392, 730811 -
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
desensitization of the soluble guanylyl cyclase/cGMP pathway by lipopolysaccharide in rat isolated pulmonary artery but not aorta, leading to muscle relaxation
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
physiological function of the enzyme in diabetes and obesity, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
role of soluble guanylate cyclase during the inflammatory phase of postoperative illius, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC contributes to the pathology of pulmonary arterial hypertension, its stimulation reverses right heart hypertrophy and structural lung vascular remodelling, hemodynamics and vascular remodelling in a rat lung model, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
soluble guanylate cyclase is a key element in NO signaling, activation of sGC is an important mechanism of vascular collapse during septic shock
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
soluble guanylate cyclase is a key element in NO signaling, activation of sGC is an important mechanism of vascular collapse duringseptic shock
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the cGMP-dependent protein kinase negatively regulates sGC activity, phosphorylation at Ser64 desensitizes sGC and dampens NO signaling, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP in form of MgGTP2-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP in form of MnGTP2-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
guanylyl cyclase-C is a peptide hormone receptor
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
guanylin-GC-C interaction, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP in form of MgGTP2-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP in form of MnGTP2-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP is a chemorepellent in Tetrahymena thermophila that stimulates cell division as well as ciliary reversal. Protein kinase C activy is not required for GTP signaling
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP is a chemorepellent in Tetrahymena thermophila that stimulates cell division as well as ciliary reversal. Protein kinase C activy is not required for GTP signaling
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
guanylate cyclase activity is nitric oxide-dependent. The recombinant enzyme shows substrate specificity for GTP rather than ATP
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
694121, 707075, 707121, 707304, 707919, 708204, 708401, 708565, 709679, 714270, 715634 -
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
isozyme RetGC1 contributes 23-28% to the maximal cGMP synthesis rate in mouse rod outer segments. The activity of isozyme RetGC2 is about 5times lower than isozyme RetGC1
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
?
-
-
-
-
?
UTP
3',5'-cyclic UMP + diphosphate
-
-
-
-
?
UTP
3',5'-cyclic UMP + diphosphate
-
-
-
-
?
additional information
?
-
-
ATP is no substrate
-
-
?
additional information
?
-
-
no considerable activity with ATP
-
-
?
additional information
?
-
-
under anaerobic conditions nitric oxide (NO) binds to the protein in its resting state (NOGC1-Fe3+) and NO still remains bound to the protein in its reduced state (NOGC1-Fe2+). NO binds to the ferri-heme (resting state) and ferroheme (reduced state) while O2 binds preferentially to ferro-heme. NO has a higher affinity for the enzyme heme site than O2
-
-
?
additional information
?
-
-
2'-deoxy-3'-GMP and cGMP exhibit no detectable affinity for the enzyme
-
-
?
additional information
?
-
-
GMPNH-P, GMPCH-P and N-methylanthraniloyl 2'-GTP are poor substrates
-
-
?
additional information
?
-
-
heme oxygenase-1 induction depletes heme and attenuates pulmonary artery relaxation and guanylate cyclase activation by nitric oxide
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
the enzyme binds the human rod Galphat protein without altering cyclase activity, interactions with ligands, overview
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
structure-function relationship, mechanism, modelling, overview
-
-
?
additional information
?
-
-
structure-function relationship, mechanism, modelling, overview
-
-
?
additional information
?
-
-
soluble guanylyl cyclase sGC provides the major guanylyl cyclase activity in Dictyostelium, contributing about 90% of the chemoattractant-induced cGMP response
-
-
?
additional information
?
-
-
structure-function relationship, overview
-
-
?
additional information
?
-
-
association of CT dinucleotide repeat polymorphism in the 5'-flanking region of the guanylyl cyclase A gene with essential hypertension in the Japanese, overview
-
-
?
additional information
?
-
-
inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2, overview
-
-
?
additional information
?
-
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart, overview
-
-
?
additional information
?
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart, overview
-
-
?
additional information
?
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart, overview
-
-
?
additional information
?
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart, overview
-
-
?
additional information
?
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart, overview
-
-
?
additional information
?
-
-
isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification, overview
-
-
?
additional information
?
-
isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification, overview
-
-
?
additional information
?
-
isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification, overview
-
-
?
additional information
?
-
isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification, overview
-
-
?
additional information
?
-
isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification, overview
-
-
?
additional information
?
-
-
isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation, overview
-
-
?
additional information
?
-
isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation, overview
-
-
?
additional information
?
-
isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation, overview
-
-
?
additional information
?
-
isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation, overview
-
-
?
additional information
?
-
isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation, overview
-
-
?
additional information
?
-
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction, overview
-
-
?
additional information
?
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction, overview
-
-
?
additional information
?
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction, overview
-
-
?
additional information
?
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction, overview
-
-
?
additional information
?
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction, overview
-
-
?
additional information
?
-
-
Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozymes GC-D and GC-G appear to be pseudogenes in the human, role of alterations of these ligand/receptor systems in human diseases, overview
-
-
?
additional information
?
-
Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozymes GC-D and GC-G appear to be pseudogenes in the human, role of alterations of these ligand/receptor systems in human diseases, overview
-
-
?
additional information
?
-
Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozymes GC-D and GC-G appear to be pseudogenes in the human, role of alterations of these ligand/receptor systems in human diseases, overview
-
-
?
additional information
?
-
Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozymes GC-D and GC-G appear to be pseudogenes in the human, role of alterations of these ligand/receptor systems in human diseases, overview
-
-
?
additional information
?
-
Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozymes GC-D and GC-G appear to be pseudogenes in the human, role of alterations of these ligand/receptor systems in human diseases, overview
-
-
?
additional information
?
-
-
sGC mediates the NO-induced aqueous humor secretion and increased outflow facility from the eye
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
splicing is a method of sGC regulation, direct regulation of guanylyl cyclase by dominant-negative splice variants. alpha1 Soluble guanylyl cyclase splice forms act as regulators of human sGC activity, overview
-
-
?
additional information
?
-
-
splicing is a method of sGC regulation, direct regulation of guanylyl cyclase by dominant-negative splice variants. alpha1 Soluble guanylyl cyclase splice forms act as regulators of human sGC activity, overview
-
-
?
additional information
?
-
-
the NO/sGC/cGMP signaling cascade is not critically involved in ODQ-induced neurite remodeling, overview
-
-
?
additional information
?
-
-
molecular basis of substrate specificity, overview
-
-
?
additional information
?
-
-
ATP-dependent mode of ANF-RGC signal transduction mechanism, overview
-
-
?
additional information
?
-
-
inhibition of soluble guanylate cyclase abolishes the potentiating effect of Mn2+ on MAP kinase phosphorylation, NF-kappaB activation, and production of NO
-
-
?
additional information
?
-
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart. Isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification. Isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation. Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozyme GC-D has chemosensory functions in the olfactory neuroepithelium
-
-
?
additional information
?
-
-
modeling of the intracellular signal transduction for CO2 detection by GC-D+ neurons and the molecular mechanism of bicarbonate sensing by GC-D, overview
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
soluble guanylyl cyclase alpha1/alpha2 subunits are involved in the relaxant effect of CO and CORM-2, i.e. CO-releasing molecule-2, on enteric smooth muscle, overview
-
-
?
additional information
?
-
-
sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil, overview
-
-
?
additional information
?
-
-
the atrial natriuretic peptide/GC-A/cGMP-dependent protein kinase I system stimulates the phosphorylation of VASP in cultured microvascular endothelial cells
-
-
?
additional information
?
-
-
structure and functions of membrane guanylate cyclase isozymes, overview
-
-
?
additional information
?
-
-
the enzyme binds the human rod Galphat protein without altering cyclase activity, overview
-
-
?
additional information
?
-
-
inhibition of soluble guanylate cyclase abolishes the potentiating effect of Mn2+ on MAP kinase phosphorylation, NF-kappaB activation, and production of NO
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
guanylate cyclase inhibitor LY-83583 completely blocks high frequency stimuli at 20 Hz/20 s-induced ganglionic long-term potentiation, gLTP, in superior cervical ganglia isolated from control rats, overview
-
-
?
additional information
?
-
-
guanylyl cyclase and protein kinase G mediate nitric oxide suppression of 5-lipoxygenase metabolism in rat alveolar macrophages, regulation mechanisms, overview
-
-
?
additional information
?
-
-
hypertension is related to reduced cGMP levels, spontaneously hypertensive rats shows reduced sGC levels, overview, sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
sGC mediates the NO-induced aqueous humor secretion and increased outflow facility from the eye
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
in vivo mechanism of GTP avoidance, overview
-
-
?
additional information
?
-
-
in vivo mechanism of GTP avoidance, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GTP
3',5'-cyclic GMP + diphosphate
GTP
3',5'-cyclic-GMP + diphosphate
additional information
?
-
GTP
3',5'-cyclic GMP + diphosphate
the receptor membrane-bound guanylate cyclase in the sperm tail triggers sperm chemotaxis, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the receptor membrane-bound guanylate cyclase in the sperm tail triggers sperm chemotaxis, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
converts GTP into cGMP in many cell types upon green light stimulation whereas it is totally inactive in the dark
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
cGMP is involved in transmitting the NO activating signals to a variety of downstream effectors such as cyclicnucleotide-gated channels, protein kinases, and phosphodiesterases
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the guanylyl cyclase messenger system is potentially responsive to hormones/neurotranmitters that may control the degree of relaxation in this vascular tissue
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC produces cGMP, a second messenger required for normal vascular smooth muscle cell, VSMC, relaxation. Activating NADPH oxidase in bovine aortic VSMC increases ROS levels and induces oxidative posttranslational modification of Cys122, a beta1-subunit cysteinyl residue of the guanylate cyclase leading to its inhibition
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme is involved in regualtion of artery contaction, enzyme activation by NO leads to increased pulmonary artery relaxation
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the retinal isozyme retGC-1 influences transducin movement, not through its cyclase activity, but through direct interaction with Galphat protein, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
soluble guanylate cyclase is the mammalian receptor for nitric oxide
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the enzyme acts as a receptor for the molt-inhibiting hormone
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the receptor guanylyl cyclase acts as a molt-inhibiting hormone receptor and is a functional link to ecdysteroidogenesis, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the enzyme produces cGMP in response to green light with a light to dark activity ratio above 1000. After light excitation the putative signaling state forms. The membrane embedded protein converts GTP into cGMP in many cell types upon green light stimulation whereas it is totally inactive in the dark
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the enzyme produces cGMP in response to green light with a light to dark activity ratio above 1000. After light excitation the putative signaling state forms. The membrane embedded protein converts GTP into cGMP in many cell types upon green light stimulation whereas it is totally inactive in the dark
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
mechanism of NO stimulation of cGMP production in airway hyperreactivity pathogenesis evoked by toluene inhalation, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
NO is a major signaling molecule in the gastrointestinal tract, and released NO inhibits muscular contraction. The actions of NO are mediated by stimulation of NO-sensitive sGC and a subsequent increase in cGMP concentration
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme has a role in neuronal degeneration
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
isozyme Gyc-89Da in neurons is necessary early in adult development to prevent eclosion, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
isozyme Gyc-89Db in neurons is necessary early in adult development to prevent eclosion, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
691340, 692206, 692546, 692585, 692704, 693102, 693364, 693365, 693784, 694977, 729139, 730028, 730957 -
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
guanylyl cyclase receptors synthesize the second-messenger cyclic GMP
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
in the heart exists a coupled multienzymatic system for selective regulation of indirect, sGC-dependent versus direct, sGC-independent NO- and redox-related modulation of voltage-gated ion channel function in different myocyte types, mechanisms, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
nitric oxide and carbon monoxide are modulators of neurotransmission in cardiac ganglia and in neural control of the adult human heart
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC contributes to the pathology of pulmonary arterial hypertension, its stimulation reverses right heart hypertrophy and structural lung vascular remodelling, hemodynamics and vascular remodelling in lung explants, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC is a receptor for nitric oxide generating cGMP
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
soluble guanylyl cyclase is a key protein in the NO/cGMP signaling pathway
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
soluble guanylyl cyclase is the principal receptor for NO and plays a ubiquitous role in regulating cellular function, sGC governs smooth muscle tone and growth, vascular permeability, leukocyte flux, and platelet aggregation. Aberrant NO-sGC signaling is linked to diseases including hypertension, atherosclerosis, and stroke
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme and cGMP-pathway are involved in NO-mediated cell migration
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme is important in regulation of cardiaovascular functions and vision in humans, allosteric regulation, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the membrane guanylate cyclase is part of a transduction machinery involving the guanylate cyclae, the guanylate cyclase activating protein type 1, S100B, and neurocalcin delta, mechanism, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the NO-independent, heme-dependent soluble guanylate cyclase acts as an NO receptor
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the retinal isozyme retGC-1 influences transducin movement, not through its cyclase activity, but through direct interaction with Galphat protein, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
von Willebrand factor/ristocetin-mediated activation of the sGC/cGMP signaling pathway may contribute to feedback platelet inhibition, regulation mechanisms, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the soluble guanylyl cyclase is the major receptor for NO and contributes to prolonged depolarization of the membrane potential in cerebral giant cells, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
atrial natriuretic factor receptor guanylate cyclase GC-A is the receptor of the atrial natriuretic factor and the type B natriuretic peptide, overview
cyclic GMP is a second messenger in controlling blood pressure, cardiac vasculature, and fluid secretion
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GC-A acts as receptor for atrial natriuretic peptide that regulates arterial blood pressure and volume, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
guanylyl cyclase receptors synthesize the second-messenger cyclic GMP
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
isozyme GC-A is a common receptor for atrial and brain natriuretic peptide
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
membrane forms of guanylyl cyclase serve as cell-surface receptors that synthesize the second messenger cGMP, which mediates diverse cellular processes. GC-G plays a role in mediating injury, GC-G may act as an early signaling molecule that promotes apoptotic and inflammatory responses in I/R-induced acute renal injury
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
NO receptor isozymes NO-GC1 and NO-GC2 are required for long term potentiation in smooth muscle relaxation, they mediate vasorelaxation and platelet-inhibition of nitric oxide being the only NO receptor of the signalling pathway
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
NO-GC plays a role in neuropathic pain. cGMP produced by NO-GC may activate signaling pathways different from cGMP-dependent protein kinase I, cGKI, during spinal nociceptive processing, whereas cGKI can be activated by natriuretic peptide receptor-B dependent cGMP production, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
role of sGCalpha1beta1 in nitrergic regulation of jejunal smooth muscle activity in male and female mice, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC contributes to the pathology of pulmonary arterial hypertension, its stimulation reverses right heart hypertrophy and structural lung vascular remodelling, hemodynamics and vascular remodelling in a mouse lung model, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice, enzyme inhibition in lung increases the filtration coefficient, regulation, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme is involved in vasorelaxation, NO acts as a signalling molecule regulating sGC expression in a negative feedback loop, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
the homodimeric transmembrane guanylyl cyclase-A receptor produces cytoplasmic cyclic GMP from GTP on binding its extracellular ligands, atrial and B-type natriuretic peptides, which modulate blood pressure and volume through the stimulation of cyclic GMP production by their guanylyl cyclase-A receptor, overview. Alternative splicing can regulate endogenous ANP/GC-A signaling, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the regulation of arterial vasodilatory and cardiac beta-adrenergic reserve by phosphodiesterase type 5-I targets cGMP from soluble GC stimulation
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the retina-specific guanylyl cyclases, retGC1 and retGC2 support synthesis of cGMP in photoreceptors
cyclic GMP serves as the second messenger in visual transduction, linking photon absorption by rhodopsin to the activity of ion channels
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the retinal isozyme retGC-1 influences transducin movement, not through its cyclase activity, but through direct interaction with Galphat protein, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the soluble guanylate cyclase isoforms alpha1beta1 and alpha2beta1 are involved in the relaxation of distal colon by exogenous NO and by NANC nerve stimulation, mechanism, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
von Willebrand factor/ristocetin-mediated activation of the sGC/cGMP signaling pathway may contribute to feedback platelet inhibition, regulation mechanisms, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice, enzyme inhibition in lung increases the filtration coefficient, regulation, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme is involved in vasorelaxation, NO acts as a signalling molecule regulating sGC expression in a negative feedback loop, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
cGMP levels in response to relaxant agonists are regulated in gastrointestinal smooth muscle by activation of phosphodiesterase 5 and inhibition of soluble guanylyl cyclase by c-Src-dependent phosphorylation in a feedback mechanism via the cGMP-dependent protein kinase, mechanism for attenuation of the NO/sGC/cGMP signal by Gi-coupled contractile agonists, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the enzyme is involved in vasorelaxation, NO acts as a signalling molecule regulating sGC expression in a negative feedback loop, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the receptor membrane-bound guanylate cyclase in the sperm tail triggers sperm chemotaxis, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
desensitization of the soluble guanylyl cyclase/cGMP pathway by lipopolysaccharide in rat isolated pulmonary artery but not aorta, leading to muscle relaxation
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
physiological function of the enzyme in diabetes and obesity, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
role of soluble guanylate cyclase during the inflammatory phase of postoperative illius, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC contributes to the pathology of pulmonary arterial hypertension, its stimulation reverses right heart hypertrophy and structural lung vascular remodelling, hemodynamics and vascular remodelling in a rat lung model, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
soluble guanylate cyclase is a key element in NO signaling, activation of sGC is an important mechanism of vascular collapse during septic shock
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
soluble guanylate cyclase is a key element in NO signaling, activation of sGC is an important mechanism of vascular collapse duringseptic shock
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
the cGMP-dependent protein kinase negatively regulates sGC activity, phosphorylation at Ser64 desensitizes sGC and dampens NO signaling, overview
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
guanylyl cyclase-C is a peptide hormone receptor
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
sGC activity plays an important role in a variety of aspects of the cardiovascular system, regulatory mechanisms, overview. sGC has an anti-proliferative effect on smooth muscle cells
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP is a chemorepellent in Tetrahymena thermophila that stimulates cell division as well as ciliary reversal. Protein kinase C activy is not required for GTP signaling
-
-
?
GTP
3',5'-cyclic GMP + diphosphate
-
GTP is a chemorepellent in Tetrahymena thermophila that stimulates cell division as well as ciliary reversal. Protein kinase C activy is not required for GTP signaling
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
3',5'-cyclic-GMP + diphosphate
-
-
-
-
?
GTP
?
-
-
-
-
?
additional information
?
-
-
heme oxygenase-1 induction depletes heme and attenuates pulmonary artery relaxation and guanylate cyclase activation by nitric oxide
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
soluble guanylyl cyclase sGC provides the major guanylyl cyclase activity in Dictyostelium, contributing about 90% of the chemoattractant-induced cGMP response
-
-
?
additional information
?
-
-
association of CT dinucleotide repeat polymorphism in the 5'-flanking region of the guanylyl cyclase A gene with essential hypertension in the Japanese, overview
-
-
?
additional information
?
-
-
inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2, overview
-
-
?
additional information
?
-
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart, overview
-
-
?
additional information
?
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart, overview
-
-
?
additional information
?
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart, overview
-
-
?
additional information
?
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart, overview
-
-
?
additional information
?
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart, overview
-
-
?
additional information
?
-
-
isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification, overview
-
-
?
additional information
?
-
isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification, overview
-
-
?
additional information
?
-
isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification, overview
-
-
?
additional information
?
-
isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification, overview
-
-
?
additional information
?
-
isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification, overview
-
-
?
additional information
?
-
-
isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation, overview
-
-
?
additional information
?
-
isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation, overview
-
-
?
additional information
?
-
isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation, overview
-
-
?
additional information
?
-
isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation, overview
-
-
?
additional information
?
-
isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation, overview
-
-
?
additional information
?
-
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction, overview
-
-
?
additional information
?
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction, overview
-
-
?
additional information
?
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction, overview
-
-
?
additional information
?
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction, overview
-
-
?
additional information
?
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction, overview
-
-
?
additional information
?
-
-
Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozymes GC-D and GC-G appear to be pseudogenes in the human, role of alterations of these ligand/receptor systems in human diseases, overview
-
-
?
additional information
?
-
Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozymes GC-D and GC-G appear to be pseudogenes in the human, role of alterations of these ligand/receptor systems in human diseases, overview
-
-
?
additional information
?
-
Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozymes GC-D and GC-G appear to be pseudogenes in the human, role of alterations of these ligand/receptor systems in human diseases, overview
-
-
?
additional information
?
-
Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozymes GC-D and GC-G appear to be pseudogenes in the human, role of alterations of these ligand/receptor systems in human diseases, overview
-
-
?
additional information
?
-
Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozymes GC-D and GC-G appear to be pseudogenes in the human, role of alterations of these ligand/receptor systems in human diseases, overview
-
-
?
additional information
?
-
-
sGC mediates the NO-induced aqueous humor secretion and increased outflow facility from the eye
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
splicing is a method of sGC regulation, direct regulation of guanylyl cyclase by dominant-negative splice variants. alpha1 Soluble guanylyl cyclase splice forms act as regulators of human sGC activity, overview
-
-
?
additional information
?
-
-
splicing is a method of sGC regulation, direct regulation of guanylyl cyclase by dominant-negative splice variants. alpha1 Soluble guanylyl cyclase splice forms act as regulators of human sGC activity, overview
-
-
?
additional information
?
-
-
the NO/sGC/cGMP signaling cascade is not critically involved in ODQ-induced neurite remodeling, overview
-
-
?
additional information
?
-
-
ATP-dependent mode of ANF-RGC signal transduction mechanism, overview
-
-
?
additional information
?
-
-
inhibition of soluble guanylate cyclase abolishes the potentiating effect of Mn2+ on MAP kinase phosphorylation, NF-kappaB activation, and production of NO
-
-
?
additional information
?
-
-
isozyme GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic and antifibrotic actions in the heart. Isozyme GC-B, the specific receptor for C-type natriuretic peptide, has a critical role in endochondral ossification. Isozyme GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and epithelial cell growth and differentiation. Isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Isozyme GC-D has chemosensory functions in the olfactory neuroepithelium
-
-
?
additional information
?
-
-
modeling of the intracellular signal transduction for CO2 detection by GC-D+ neurons and the molecular mechanism of bicarbonate sensing by GC-D, overview
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
soluble guanylyl cyclase alpha1/alpha2 subunits are involved in the relaxant effect of CO and CORM-2, i.e. CO-releasing molecule-2, on enteric smooth muscle, overview
-
-
?
additional information
?
-
-
sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil, overview
-
-
?
additional information
?
-
-
the atrial natriuretic peptide/GC-A/cGMP-dependent protein kinase I system stimulates the phosphorylation of VASP in cultured microvascular endothelial cells
-
-
?
additional information
?
-
-
inhibition of soluble guanylate cyclase abolishes the potentiating effect of Mn2+ on MAP kinase phosphorylation, NF-kappaB activation, and production of NO
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
guanylate cyclase inhibitor LY-83583 completely blocks high frequency stimuli at 20 Hz/20 s-induced ganglionic long-term potentiation, gLTP, in superior cervical ganglia isolated from control rats, overview
-
-
?
additional information
?
-
-
guanylyl cyclase and protein kinase G mediate nitric oxide suppression of 5-lipoxygenase metabolism in rat alveolar macrophages, regulation mechanisms, overview
-
-
?
additional information
?
-
-
hypertension is related to reduced cGMP levels, spontaneously hypertensive rats shows reduced sGC levels, overview, sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
sGC mediates the NO-induced aqueous humor secretion and increased outflow facility from the eye
-
-
?
additional information
?
-
-
sGC role in vascular system diseases and failures, overview
-
-
?
additional information
?
-
-
in vivo mechanism of GTP avoidance, overview
-
-
?
additional information
?
-
-
in vivo mechanism of GTP avoidance, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
17beta-estradiol
-
decreases enzyme activity in immature rats, while the amount of sGC alpha subuit increases, estrogen receptor-dependent effects, overview
1H-(1,2,4)-oxadiazole-(4,3-a)quinoxalin-1-one
-
-
1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one
1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1one
1H-[1,2,4] oxadiazole [4,3-a] quinoxalin-1-one
-
effectively blocks guanylyl cyclase activity in response to low O2 levels
1H-[1,2,4]-oxadiazole[4,3-a]quinoxalin-1-one
i.e. ODQ, a highly selective sGC inhibitor; i.e. ODQ, a highly selective sGC inhibitor
1H-[1,2,4]oxadiazolo [4,3,-a]quinoxalin-1-one
1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one
-
i.e. ODQ, a sGC inhibitor
1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one
i.e. ODQ
1H-[1,2,4]oxadiazolo[4,3-a]-quinoxalin-1-one
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin 1-one
decreases infectivity of promastigotes
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline-1-one
-
-
1H-[1,2,4]oxadiazolo[4,3a]quinoxalin-1-one
1H-[1,2,4]oxadiazolo[4.3a]quinoxalin-1-one
-
inhibition of the enzyme is blocked by 8-bromo-cGMP or L-arginine
2'(3')-O-BODIPY-FL-guanosine 5'-[beta,gamma-imido]triphosphate
-
-
2',3'-O-(2,4,6-trinitrophenyl)-ADP
-
-
2',3'-O-(2,4,6-trinitrophenyl)-AMP
-
-
2',3'-O-(2,4,6-trinitrophenyl)-ATP
-
-
2',3'-O-(2,4,6-trinitrophenyl)-CTP
-
-
2',3'-O-(2,4,6-trinitrophenyl)-GDP
-
-
2',3'-O-(2,4,6-trinitrophenyl)-GTP
-
-
2',3'-O-(2,4,6-trinitrophenyl)-UTP
-
-
2'-dADP
-
mixture of competitive and noncompetitive inhibition, binding to the substrate site excludes the substrate GTP, whereas binding to the noncompetitive site has no effect on GTP binding, although the resulting complex is catalytically inactive. It binds to the high and low affinity sites with equivalent affinities. BAY 41-2272, which shares an analogous core structure to YC-1, fully inhibits 2'-dADP binding to the low affinity site, whereas the inhibition by YC-1 is incomplete
2'-deoxy-3'-O-(N-methylanthraniloyl)-ATP
-
-
2'-deoxy-3'-O-(N-methylanthraniloyl)-GDP
-
-
2'-deoxy-3'-O-(N-methylanthraniloyl)-GTP
-
-
2'-deoxy-3'-O-(N-methylanthraniloyl)-guanosine 5'-[beta,gamma-imido]triphosphate
-
-
3',5'-cyclic GMP
20 mM, 20-30% competitive inhibition
4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
6-(ethoxymethyl)-1-methyl-1,4,5,6-tetrahydropyrrolo[2,3-g]indazole
-
-
6-(ethoxymethyl)-1-phenyl-1,4,5,6-tetrahydropyrrolo[2,3-g]indazole
-
-
6-(ethoxymethyl)-5,6-dihydro-4H-[1,2]oxazolo[5,4-e]indole
-
-
6-(ethoxymethyl)-6H-[1,2]oxazolo[5,4-e]indole
-
-
6-anilino-5,8-quinolinedione
6-anilino-quinoline-5-8-quinone
decreases infectivity of promastigotes
6H-[1,2,4]oxadiazolo[4,3-d]pyrido[3,2-b][1,4]oxazin-9-one
-
-
8-(4-methoxyphenyl)-4H-[1,2,4]oxadiazolo[3,4-c][1,4]-benzoxazin-1-one
-
-
8-aza-3ATP
-
inhibition of basal and sodium nitroprusside activated sGC activity
8-bromo-4H-[1,2,4]oxadiazolo[3,4-c]benzoxazin-1-one
-
NS 2028
8-bromo-4H-[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-1-one
-
i.e. NS-2028, a selective sGC inhibitor, 95% inhibition of enzyme activity at 0.01 mM, inhibits cell proliferation
8-oxoguanosine triphosphate
8-[3-(trifluoromethyl)phenyl]-4H-[1,2,4]oxadiazolo[3,4-c]-benzoxazin-1-one
-
-
9-chloro-12-oxo-6,12-dihydroquinazolino[2,3-c][1,4]-benzoxazine
-
-
adenosine 5'-beta,gamma-imido triphosphate
-
competitive inhibitor, reduces the Bmax for the binding of guanosine 5'-beta,gamma-methylene triphosphate, is tightly and selectively associated with the high affinity site
adenosine-5'-tetraphosphate
-
basal activity of wild-type enzyme is considerably less sensitive than NO-stimulated wild-type activity
ADPbetaS
-
basal activity of wild-type enzyme is considerably less sensitive than NO-stimulated wild-type activity
aldosterone
-
diminishes GC activity by activating NADPH oxidase in bovine aortic VSMC to increase ROS levels and induce oxidative posttranslational modification of Cys122, a beta1-subunit cysteinyl residue
atrial natriuretic peptide
-
elicits GC-A desensitization, can induce decreased GC-A activity in MA-10 Leydig cells, based on mechanisms directly affecting the hormone responsiveness of the receptor. Protein kinase A blocks homologous atrial natriuretic peptide induced desensitization, in which cGMP is generated as second messenger
-
BaY 63-2521
-
the sGC inhibitor gives apositive effect in severe pulmonary hypertention patients
Ca2+ ionophore A23187
-
Ca2+-dependent inhibition of sGC can be achieved with the Ca2+ ionophore A23187 (0.01 mM)
Calmidazolium
-
uncompetitive inhibition, time-dependent inhibition at 0.03 mM, pre-treatment of sGC with calmidazolium, followed by filtration, causes an 80% inhibition of sGC activation by nitric oxide and a 23% inhibition of activation by protoporphyrin IX
CO
-
forms stable complexes with Gyc-88E(1-597), inhibits 2.9fold
D-myo-inositol 1,4,5-trisphosphate
-
-
DNIC-G
-
a dinitrosyl iron complex, solutions contain 18fold molar excess of free thiosulfate, inhibition of the NO-stimulated enzyme, inhibited by GSH
DNIC-Y
-
a dinitrosyl iron complex, no free thiosulfate in solutions of the binuclear complex DNIC-Y, inhibition of the NO-stimulated enzyme, inhibited by GSH
GDPbetaS
-
basal activity of wild-type enzyme is considerably less sensitive than NO-stimulated wild-type activity
Go6976
-
competitive inhibitor. Go6976 reduces GTP binding to the catalytic site of isoforms GC-A and GC-B. Inhibition of isoform GC-B is minimal in the absence of ATP and 1 mM ATP increases the inhibition 4fold
GTPgammaS
-
inhibits mastoparan-induced activation
guanosine 5'-(beta,gamma-imido)triphosphate
-
-
guanosine tetrakisphosphate
-
-
guanosine-5'-tetraphosphate
-
basal activity of wild-type enzyme is considerably less sensitive than NO-stimulated wild-type activity
guanylyl cyclase activating protein 1
-
GCAP1, a Ca2+/Mg2+-binding protein, metal binding in EF-hand 4 has no role in the primary attachment of GCAP1 to the cyclase, it only triggers the activator-to-inhibitor functional switch in GCAP1, differential binding of GCAP1 mutants, e.g. E75Q/E111Q/E155Q or D100N/D102G mutants, to RetGC1 in HEK-293 cells, overview
-
H2O2
-
diminishes GC activity by activating NADPH oxidase in bovine aortic VSMC to increase ROS levels and induce oxidative posttranslational modification of Cys122, a beta1-subunit cysteinyl residue
HS-142-1
-
natriuretic peptide released from the heart with acute heart failure target particulate GC, results in a decrease in UNaV and cGMP excretion together with a reduction in glomerular filtration rate and an increase in distal fractional tubular sodium reabsorption
lauryldimethyl N-oxide
-
-
LY-83583
-
inhibits the enzyme and completely blocks at 5 mM high frequency stimuli at 20 Hz/20 s-induced gLTP in superior cervical ganglia isolated from control rats
LY83583
-
a selective sGC inhibitor
lysophosphatidic acid
-
preincubations for 30 min before assessments of atrial natriuretic peptide-induced cGMP generation reveals inhibitory effects, exerted in a dose-dependent manner, elicits GC-A desensitization, protein kinase A does not block lysophosphatidic acid-induced heterologous desensitization. MEK inhibitor PD 98059 does not protect against the lysophosphatidic acid-mediated decrease in GC-A hormone sensitivity
Mg2+ATPgammaS
-
inhibits cyclase activity through a mixed, non-competitive mechanism, only observable under NO stimulation and not under basal conditions
Mg2+GTPgammaS
-
inhibits cyclase activity through a mixed, non-competitive mechanism, only observable under NO stimulation and not under basal conditions
N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine
-
-
N-methylanthraniloyl-adenosine 5'-[beta,gamma-imido]triphosphate
-
-
N-methylanthraniloyl-ADP
-
-
N-methylanthraniloyl-ATP
-
-
N-methylanthraniloyl-GDP
-
-
N-methylanthraniloyl-GTP
-
-
N-methylanthraniloyl-GTPgammaS
-
-
N-methylanthraniloyl-guanosine 5'-[beta,gamma-imido]triphosphate
-
-
N-methylanthraniloyl-ITPgammaS
-
-
N-methylanthraniloyl-xanthosine 5'-[beta,gamma-imido]triphosphate
-
-
N-methylanthraniloyl-XDP
-
-
NaCl
-
80% inhibition at 0.2 mM, affects C-type NP 1-53 stimulation of the enzyme
O2
-
forms stable complexes with Gyc-88E(1-597), inhibits 3.2fold
ONE-GC 880MGTTVEPEYFDQVTIYFSDIVG901
-
causes ca. 90% inhibition
ONE-GC 900VGFTTISALSEPIEVVGFLNDL921
-
most effective inhibitor, causes ca. 95% inhibition
phosphodiesterase inhibitor dipyridamole
-
-
-
potassium thiocyanate
-
-
protein phosphatase from spermatozoa
-
-
-
S-nitrosocysteine
-
inhibition of sGC activity by S-nitrosocysteine occurs only in parallel with the loss of cellular glutathione suggesting that loss of sGC activity may occur as a result of the severe depletion of the reduced thiol pool that occurs after exposure of cells to S-nitrosocysteine
sGC alpha1 splice variant
inhibits the enzyme, no co-precipitation of the N1-alpha1 sGC with the beta-subunit
-
sodium lauryl sarcosinate
-
-
tetanus toxin
expression of tetanus toxin in the neurons, that express isozyme Gyc-89Da, blocks their synaptic activity; expression of tetanus toxin in the neurons, that express isozyme Gyc-89Db, blocks their synaptic activity
-
thrombospondin-1
-
thrombospondin-1 is a universal inhibitor of sGC, blocking both hemedependent and heme-independent activation
-
XDP
-
basal activity of wild-type enzyme is considerably less sensitive than NO-stimulated wild-type activity
XTP
-
basal activity of wild-type enzyme is considerably less sensitive than NO-stimulated wild-type activity
zinc (II) protophorphyrin IX
-
at higher concentrations, 2.5 µM
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
-
-
1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one
-
-
1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one
-
-
1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1one
0.1 mM, complete inhibition
1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1one
-
-
1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1one
-
specific inhibitor of sGC
1H-[1,2,4]oxadiazolo [4,3,-a]quinoxalin-1-one
-
i.e. ODQ
1H-[1,2,4]oxadiazolo [4,3,-a]quinoxalin-1-one
i.e. ODQ, in vivo treatment with the sGC inhibitors ODQ does not decrease plasmatic and jejunal cGMP levels, nor does it influence the change in electrical field-induced relaxation; i.e. ODQ, in vivo treatment with the sGC inhibitors ODQ does not decrease plasmatic and jejunal cGMP levels, nor does it influence the change in electrical field-induced relaxation
1H-[1,2,4]oxadiazolo[4,3-a]-quinoxalin-1-one
-
guanylyl cyclase inhibitor, completely abrogates chemotactic and chemokinetic cellular movement to both diethylamine/NO and diethylenetriamine/NO exposure
1H-[1,2,4]oxadiazolo[4,3-a]-quinoxalin-1-one
-
specific sGC inhibitor, significantly blocks the capsaicin-induced reduction of mechanical threshold to noxious stimulation of the masseter
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
-
i.e. ODQ, inhibits the enzyme, and also inhibits Y-27632- and staurosporine-induced neurite outgrowth and triggered neurite retraction, but in an sGC-independent manner. The NO/sGC/cGMP signaling cascade is not, but the the ERK signaling pathway is critically involved in ODQ-induced neurite remodeling
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
-
-
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
-
i.e.ODQ, a sGC inhibitor
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
-
a soluble guanylate cyclase inhibitor, maximal inhibition (70%) at 0.01 mM
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
-
-
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
-
complete inhibition at 0.001 mM
1H-[1,2,4]oxadiazolo[4,3a]quinoxalin-1-one
-
i.e. ODQ
1H-[1,2,4]oxadiazolo[4,3a]quinoxalin-1-one
-
acute addition to pulmonary artery does not affect phenylephrine responsiveness, but restores the responsiveness in pulmonary artery treated with an NO-donor, overview
4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
-
i.e. NS-2028, acts via the heme domain
4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
-
i.e. NS-2028, acts via the heme domain
4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
-
i.e. NS-2028, acts via the heme domain
4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
-
NS-2028, a soluble guanylyl cyclase inhibitor, complete inhibition at 0.01 mM
4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
-
i.e. NS-2028, acts via the heme domain
4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
-
i.e. NS-2028, acts via the heme domain
4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
i.e. NS-2028, acts via the heme domain
4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
-
i.e. NS-2028, acts via the heme domain
4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
-
i.e. NS-2028, acts via the heme domain
6-anilino-5,8-quinolinedione
-
-
6-anilino-5,8-quinolinedione
-
-
6-anilino-5,8-quinolinedione
-
-
6-anilino-5,8-quinolinedione
-
-
6-anilino-5,8-quinolinedione
-
-
6-anilino-5,8-quinolinedione
-
6-anilino-5,8-quinolinedione
-
-
6-anilino-5,8-quinolinedione
-
-
8-oxoguanosine triphosphate
-
i.e. oxo8GTP, a potent inhibitor of nitric oxide-stimulated soluble guanylyl cyclase
8-oxoguanosine triphosphate
-
i.e. oxo8GTP, a potent competitive inhibitor of nitric oxide-stimulated soluble guanylyl cyclase
ATP
-
-
ATP
-
mechanism involving ATP pre-binding is physiologically relevant to activation of retinal guanylate cyclase, inhibition at high concentrations
ATP
-
80% inhibition at 0.1 mM, affects C-type NP 1-53 stimulation of the enzyme, in the presence of Mn2+ inhibition of mastoparan-induced activation of the enzyme
ATP
-
inhibition by ATP of GC activity stimulated by NO
ATP
-
allosteric inhibition of basal and sodium nitroprusside activated sGC activity
ATP
inhibits the enzyme by 70% at 1 mM in presence of stoichiometric concentrations of NO
ATP
-
in solubilized membranes ATP exerts an inhibitory role on basal and atrial natriuretic peptide 1-28-induced GC activity
Ba2+
-
-
Ca2+
-
-
Ca2+
-
inhibition of both, the basal and NO-stimulated forms of sGC, competitive vs. Mg2+, noncompetitive vs. MgGTP
Ca2+
-
0.00005 mM, 50% inhibition
Ca2+
-
0.0002 mM, 50% inhibition
Ca2+
-
modulates the membrane guanylate cyclase transduction machinery by both inhibiting and stimulating it involving the guanylate cyclae, the guanylate cyclase activating protein type 1, S100B, and neurocalcin delta, mechanism, overview
Ca2+
-
the enzyme is inhibited by high intracellular Ca2+ concentration
Cd2+
-
-
Co2+
-
-
Cu2+
-
-
dGTP
-
-
diphosphate
-
-
diphosphate
competitive inhibition
Hg2+
-
-
ITP
-
-
ITP
-
basal activity of wild-type enzyme is considerably less sensitive than NO-stimulated wild-type activity
LY 83583
-
i.e. 6-anilino-5,8-quinoledione
methylene blue
-
-
methylene blue
-
a nonspecific sGC inhibitor
methylene blue
-
non-specific sGC inhibitor, significantly blocks the capsaicin-induced reduction of mechanical threshold to noxious stimulation of the masseter
methylene blue
inhibits by oxidation of the enzyme's ferrous heme; inhibits by oxidation of the enzyme's ferrous heme
methylene blue
in vivo treatment with the sGC inhibitor methylene blue does not decrease plasmatic and jejunal cGMP levels, nor does it influence the change in electrical filed stimulation-induced relaxation; in vivo treatment with the sGC inhibitor methylene blue does not decrease plasmatic and jejunal cGMP levels, nor does it influence the change in electrical filed stimulation-induced relaxation
NO
-
forms stable complexes with Gyc-88E(1-597), inhibits 2fold
NO
-
long acting NO donors pentaerythrityl tetranitrate and isosorbide mononitrate have a significant impact on the regulation of vascular sGC expression and activity, overview
NO
-
long acting NO donors pentaerythrityl tetranitrate and isosorbide mononitrate have a significant impact on the regulation of vascular sGC expression and activity, overview
NS-2028
a potent sGC inhibitor
oxaloacetate
-
-
phosphoenolpyruvate
-
-
superoxide
-
-
UTP
-
-
Zn2+
-
-
Zn2+
-
0.08 mM, 50% inhibition of the intracellular domain of GCC catalytic activity
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
-
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
-
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
i.e. QDC, a selective sGC inhibitor, inhibits cell proliferation
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
-
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
inhibits the enzyme and the enzyme activating effect of sodium nitroprusside
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
-
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
-
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
-
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
-
additional information
-
the ATP analogs ATP-Sp-alphaS and ATP-Rp-alphaS are potent inhibitors
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
desensitization of the enzyme to NO and inactivation of soluble guanylate cyclase by stoichiometric S-nitrosation through dinitrosyl iron complexes, which is slowly reversible by GSH, overview
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
the ATP analogs ATP-Sp-alphaS and ATP-Rp-alphaS are potent inhibitors
-
additional information
-
the ATP analogs ATP-Sp-alphaS and ATP-Rp-alphaS are potent inhibitors
-
additional information
-
heme moiety of sGC has some inhibitory function on sGC activity
-
additional information
-
competitive GC-C isozyme inhibition by exogenous 18-residue heat-stable enterotoxins, STa, produced by diarrheagenic bacteria, binding to GC-C by quantifying competitive displacement of [125I]STa from GC-C expressed in membranes, overview
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
inhibition of the enzyme is involved in inhibition of tumor cell migration in lung
-
additional information
-
inhibition of soluble guanylyl cyclase requires binding to cell-surface receptor CD47. A thrombospondin-1 C-terminal fragment (E3CaG1) readily inhibits sGC in Jurkat T cells. This inhibition requires an increase in intracellular Ca+ concentration. Addition of angiotensin II also strongly inhibits soluble guanylyl cyclase activity by increasing intracellular Ca+ concentration
-
additional information
sGC is influenced by the light conditions, overview
-
additional information
-
sGC is influenced by the light conditions, overview
-
additional information
native and recombinant enzyme unaffected by chlorpromazine and trifluoprazine
-
additional information
-
native and recombinant enzyme unaffected by chlorpromazine and trifluoprazine
-
additional information
-
competitive GC-C isozyme inhibition by exogenous 18-residue heat-stable enterotoxins, STa, produced by diarrheagenic bacteria, Ki values of 1.5-57.6 nM, binding to GC-C by quantifying competitive displacement of [125I]STa from GC-C expressed in membranes, overview
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
c-Src-dependent phosphorylation of sGC in induced by acetylcholine and inhibits NO-sensitive sGC activity and cGMP production
-
additional information
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
the N-terminal heme-bound regulatory domain of the beta1 subunit of soluble guanylate cyclase inhibits the activity of the alphacatbetacat complex in trans, suggesting a domain-scale mechanism of regulation by NO
-
additional information
-
phosphorylation at Ser64 of the alpha1 subunit inhibits the enzyme
-
additional information
-
desensitization of the soluble guanylyl cyclase/cGMP pathway by lipopolysaccharide in rat isolated pulmonary artery but not aorta
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
12-oxo-6,12-dihydroquinazolino[2,3-c][1,4]benzoxazine, 2-bromo-12-oxo-6,12-dihydroquinazolino[2,3-c][1,4]-benzoxazine, and 8-bromo-2,4-dihydro-1H-[1,2,4]triazolo[3,4-c][1,4]-benzoxazin-1-one do not exhibit an inhibitory effect on sGC
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(R)-3',5-dihydroxy-4',7-dimethoxyspiro(2H-1-benzopyran-3(4H)-7'-bicyclo[4.2.0]-octa[1,3,5]-trien)4-one
-
activates the soluble guanylate cyclase exhibiting a vasorelaxing effect on the aortic ring, the compound is isolated from bulbs of South African Hyacinthaceae, i.e. Drimiopsis maculata, Eucomis schiffii, Urginea epigea, Drimia altissima, mass spectrometric identification. The compound counteracts vasocontractory agents, overview
(Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-diolate
-
sGC ferrous-nitrosyl complex adopts two 5-coordinate conformations, a lower activity closed form, which releases NO slowly, and a higher activity open form, which releases NO rapidly
1-benzyl-3-(hydroxymethyl-2-furyl)indazole
-
trivial name YC-1, allosteric activator, synergistically increases the catalytic activity in the presence of NO
2'-deoxy-3'-GMP
-
the addition of the effector to CO-activated enzyme causes the original 6-coordinate CO-heme to convert to an end product that is an equimolar mixture of a 5- and a new 6-coordinate CO-heme
2'-deoxy-ATP
-
poor allosteric activator
2'-deoxy-GTP
-
poor allosteric activator
2,2-diethyl-1-nitroso-oxyhydrazine
2-(N,N-diethylamino)-diazenolate-2-oxide
-
stimulates 4.3fold
2-(N,N-diethylamino)diazenolate-2-oxide
-
the wild type enzyme shows 59fold stimulation of activity at 0.001 mM 2-(N,N-diethylamino)diazenolate-2-oxide
2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5(4-morpholinyl)-4,6-pyrimidinediamine
-
trivial name BAY 41-8543, 66fold activation at 0.1 mM, strong synergistic activation in the presence of NO
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
-
0.2 mM, 80fold activation of recombinant sGC
3-(5'-hydroxymethyl-2'-furylf)-1-benzylimdazole
-
activation
3-(5'-hydroxymethyl-2'furyl)-1-benzyl-indazole
0.1 mM, approx. 50fold stimulation, more than 2000fold stimulation in the presence of 0.1 mM sodium prusside
3-(5'-hydroxymethyl-3'-furyl)-1-benzylindazole
-
-
3-ethyl-3-(ethylaminoethyl)-1-hydroxy-2-oxo-1-triazene
3-morpholinosydnonimine
-
i.e. SIN-1
4-((4-carboxybutyl){2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl[benzoic]acid
-
NO- and heme-independent sGC activator, stimulates 15fold, stimulation increases up to 30fold in the presence of 1H-(1,2,4)-oxadiazole-(4,3-a)-quinoxalin-1-one
4-[((4-carboxybutyl){2-[(4-phenethylbenzol)oxy]phenethyl}amino)methyl] benzoic acid
-
trivial name BAY 58-2667, heme-independent activator, 30fold activation at 0.01 mM
5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine
-
NO-independent but heme-dependent sGC stimulator, stimulates the enzyme in a concentration-dependent manner
5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine
-
-
5-[1-(phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol
-
the wild type enzyme shows 6fold stimulation of activity at 0.1 mM
Activator protein
-
from rat lung
-
adenosine 5'-[beta,gamma-imido]triphosphate
-
activation
adenylylimidophosphate
-
activation
arachidonic acid peroxide
-
activation
ATPgammaS
-
is more effective than ATP on glomerular and papillary membranes, has little effect on GC activity in solubilized membranes
atrial natriuretic factor
-
binding the hormone to the GC-A extracellular domain activates its intracellular catalytic domain, overview
-
atrial natriuretic peptide
-
atrial natriuretic peptide 1-28
-
increases GC enzymatic activity of glomerular and papillary membranes in a concentration-dependent manner
-
B-type natriuretic peptide
-
-
BAY41-2272
i.e. 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine
bicarbonate
-
activates cGMP-producing ability of guanylyl cyclase-D, a membrane guanylate cyclase exclusively expressed in the CO2-responsive olfactory sensory neurons, by directly acting on the intracellular cyclase domain of GC-D. The molecular mechanism for pH-independent GC-D activation is distinct from the release-from-repression model for other membrane guanylate cyclases, overview
brain natriuretic peptide
-
C-type natriuretic peptide
-
C-type NP 1-53
-
activation in a dose-dependent manner
-
cAMP
-
maximum activation at concentrations of 1-10 mM
CFM-1571
-
stimulator of the NO-independent, heme-dependent soluble guanylate cyclase, acts independently of and in synergism with NO producing anti-aggregatory, anti-proliferative, and vasodilatory effects, overview
cone-specific calcium sensor guanylate cyclase activating protein 4
-
CORM-2
-
i.e. CO-releasing molecule-2, a tricarbonyldichlororuthenium(II) dimer
-
D-glucose
-
D-glucose in concentrations of 0.1-10 mM clearly stimulates activity
diethylamine/NO
-
increases chemotaxis
diethylenetriamine nitric oxide
-
-
diethylenetriamine/NO
-
increases chemotaxis
Foscarnet
-
the addition of the effector to CO-activated enzyme causes the original 6-coordinate CO-heme to convert to an end product that is an equimolar mixture of a 5- and a new 6-coordinate CO-heme
G protein alpha subunit
-
GCAP1
activating protein. At near-saturating concentrations, GCAP1 and GCAP2 activate RetGC1 from HEK293 in a non-additive fashion. GCAP1 mutant M26R binds but does not activate RetGC1 and suppresses activation of recombinant and native RetGC1 by competing with both GCAP1 and GCAP2
-
GCAP2
activating protein. At near-saturating concentrations, GCAP1 and GCAP2 activate RetGC1 from HEK293 in a non-additive fashion. Deletion of a residues Tyr1016-Ser1103 fragment in RetGC1 does not block GCAP2 binding to the cyclase. Substitutions in the kinase homology domain, W708R and I734T, linked to Leber congenital amaurosis prevent binding of both GCAP1-GFP and GCAP2-GFP
-
guanosine 5'O-(thio)-triphosphate
-
activation
guanylate-activating protein
-
proteins GCAP-1 and GCAP-2, Ca2+-dependent negative feedback control
-
guanylyl cyclase activating protein
-
the native RetGC isozymes are accelerated 5-28fold at physiological concentrations of guanylyl cyclase activating proteins GCAP1 and GCAP2
-
guanylyl cyclase activating protein 1
-
GCAP1, a Ca2+/Mg2+-binding protein, after substitution of Ca2+ by Mg2+ in its EF-hands, stimulates photoreceptor guanylyl cyclase, RetGC1, in response to light. Metal binding in EF-hand 2 is crucial for GCAP1 attachment to RetGC1, while in EF-hand 3 it is less critical, although it enhances the efficiency of the GCAP1 docking on the target enzyme. Metal binding in EF-hand 4 has no role in the primary attachment of GCAP1 to the cyclase, it only triggers the activator-to-inhibitor functional switch in GCAP1, differential binding of GCAP1 mutants, e.g. E75Q/E111Q/E155Q or D100N/D102G mutants, to RetGC1 in HEK-293 cells, overview
-
H2O2
-
activates the enzyme, and reduces the cGMP formation activation by nitroprusside and BAY 41-2272 in smooth muscle cells, but enhances the response to HMR-1766, the activation by reactive oxigen species is heme-dependent
heat-stable enterotoxin
-
-
-
HMR 1766
-
activates the NO- and haem-independent soluble guanylate cyclase, compound is capable of selectively activating the oxidized/haem-free enzyme via binding to the enzyme's haem pocket, causing pronounced vasodilatation
mastoparan
-
most powerful activator, activation in a dose-dependent manner
meso-porphyrin IX
-
heme-independent activator
N-(beta-D-glucopyranosyl-N2-acetyl-S-nitroso-D,L-penicillaminamide)
-
NO donor
N2,2'-O-dibutyryl-cGMP
-
activation
neurocalcin
-
in the presence of the semimicromolar range of free Ca2+, neurocalcin binds to the catalytic module and stimulates ONE-GC, M880-L921 region of ONE-GC is the Ca2+-dependent neurocalcin binding and the transduction site of ONE-GC
-
neurocalcin sigma
-
dose-dependent stimulation in presence of the 0.01 mM Ca2+, 8fold over the basal value at ca. 0.002 mM
-
neuronal calcium sensor GCAP1
-
confers Ca2+ sensitivity to guanylyl cyclase activity
-
neuronal calcium sensor GCAP2
-
confers Ca2+ sensitivity to guanylyl cyclase activity, absence of GCAP2 affected guanylyl cyclase activity in two ways: 1. the maximal rate of cGMP synthesis at low [Ca2] dropps 2fold and 2. the half-maximal rate of cGMP synthesis is attained at a higher than normal [Ca2+], phenotype of GCAP2 knockout mice, overview
-
nitroglycerin
-
induces vasorelaxation through release of NO, and causes reversible S-nitrosylation of sGC and desensitization in primary aortic smooth muscle cells, which is prevented by N-acetylcysteine
nitrosobutane
-
6fold activation in absence of 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole, 47fold activation in presence of 0.15 mM 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole
nitrosohexane
-
2fold activation in absence of 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole, 33fold activation in presence of 0.15 mM 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole
nitrosooctane
-
2fold activation in absence of 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole, 11fold activation in presence of 0.15 mM 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole
nitrosopentane
-
2fold activation in absence of 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole, 39fold activation in presence of 0.15 mM 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole
nitrosopropane
-
2fold activation in absence of 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole, 45fold activation in presence of 0.15 mM 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole
peroxynitrite
-
activation in presence of GSH
phenylhydrazine
-
acivation
prostaglandin endoepoxide analogs
-
activation
-
protoporphyrin-IX
-
the wild type enzyme shows 1.9fold stimulation of activity at 0.1 mM and 12fold stimulation at 0.01 mM
riociguat
-
i.e. BAY 63-2521, a soluble guanylate cyclase stimulator, acts directly, stimulates the enzyme, and increases the sensitivity to low NO levels. It significantly improves pulmonary haemodynamic parameters and cardiac index in patients with pulmonary hypertension
S-nitroso-N-acetylpenicillamine
-
the wild type enzyme shows 14.5fold stimulation of activity at 0.1 mM
S-nitrosoglutathione
-
stimulates the enzyme activity via NO production, stimulation is inhibited by acetylcholine
unsaturated fatty acids
-
activation
-
uroguanylin
-
stimulates ONE-GC through its external domain in a dose-dependent fashion
von Willebrand factor/ristocetin
-
[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one
-
potentiates the activating effect of HMR-1766 on the wild-type enzyme
2,2-diethyl-1-nitroso-oxyhydrazine
-
70-80% activation at 0.01 mM in presence of 2 mM GSH
2,2-diethyl-1-nitroso-oxyhydrazine
-
0.1 mM, 87fold increase in activity, NO-relasing substance
2,2-diethyl-1-nitroso-oxyhydrazine
-
NO donor, 0.1 mM, 242fold activation
3-ethyl-3-(ethylaminoethyl)-1-hydroxy-2-oxo-1-triazene
stimulates via release of NO
3-ethyl-3-(ethylaminoethyl)-1-hydroxy-2-oxo-1-triazene
-
i.e. NOC-12
A-350619
-
a heme-dependent stimulator of sGC, structurally not related to YC-1, but synergistic to YC-1 and sodium nitroprusside for the binding site
A-350619
-
a heme-dependent stimulator of sGC, structurally not related to YC-1, but synergistic to YC-1 and sodium nitroprusside for the binding site
A-350619
-
a heme-dependent stimulator of sGC, structurally not related to YC-1, but synergistic to YC-1 and sodium nitroprusside for the binding site
A-350619
-
a heme-dependent stimulator of sGC, structurally not related to YC-1, but synergistic to YC-1 and sodium nitroprusside for the binding site
A-350619
-
a heme-dependent stimulator of sGC, structurally not related to YC-1, but synergistic to YC-1 and sodium nitroprusside for the binding site
A-350619
a heme-dependent stimulator of sGC, structurally not related to YC-1, but synergistic to YC-1 and sodium nitroprusside for the binding site
A-350619
-
a heme-dependent stimulator of sGC, structurally not related to YC-1, but synergistic to YC-1 and sodium nitroprusside for the binding site
A-350619
-
a heme-dependent stimulator of sGC, structurally not related to YC-1, but synergistic to YC-1 and sodium nitroprusside for the binding site, 70fold activation as sole stimulator, 160fold in presence of YC-1 and 230fold in presence of sodium nitroprusside
A-778935
-
i.e. cis-3-[2-(2,2-dimethyl-propylsulfanyl)pyridin-3-yl]-N-(3-hydroxycyclohexyl-)acrylamide, derived from the YC-1 structure, activates the enzyme is a synergistic fashion with the NO donor sodium nitroprusside
A-778935
-
i.e. cis-3-[2-(2,2-dimethyl-propylsulfanyl)pyridin-3-yl]-N-(3-hydroxycyclohexyl-)acrylamide, derived from the YC-1 structure, activates the enzyme is a synergistic fashion with the NO donor sodium nitroprusside
A-778935
-
i.e. cis-3-[2-(2,2-dimethyl-propylsulfanyl)pyridin-3-yl]-N-(3-hydroxycyclohexyl-)acrylamide, derived from the YC-1 structure, activates the enzyme is a synergistic fashion with the NO donor sodium nitroprusside
A-778935
-
i.e. cis-3-[2-(2,2-dimethyl-propylsulfanyl)pyridin-3-yl]-N-(3-hydroxycyclohexyl-)acrylamide, derived from the YC-1 structure, activates the enzyme is a synergistic fashion with the NO donor sodium nitroprusside
A-778935
-
i.e. cis-3-[2-(2,2-dimethyl-propylsulfanyl)pyridin-3-yl]-N-(3-hydroxycyclohexyl-)acrylamide, derived from the YC-1 structure, activates the enzyme is a synergistic fashion with the NO donor sodium nitroprusside
A-778935
i.e. cis-3-[2-(2,2-dimethyl-propylsulfanyl)pyridin-3-yl]-N-(3-hydroxycyclohexyl-)acrylamide, derived from the YC-1 structure, activates the enzyme is a synergistic fashion with the NO donor sodium nitroprusside
A-778935
-
i.e. cis-3-[2-(2,2-dimethyl-propylsulfanyl)pyridin-3-yl]-N-(3-hydroxycyclohexyl-)acrylamide, derived from the YC-1 structure, activates the enzyme is a synergistic fashion with the NO donor sodium nitroprusside
A-778935
-
i.e. cis-3-[2-(2,2-dimethyl-propylsulfanyl)pyridin-3-yl]-N-(3-hydroxycyclohexyl-)acrylamide, derived from the YC-1 structure, activates the enzyme is a synergistic fashion with the NO donor sodium nitroprusside
ATP
-
mechanism involving ATP pre-binding is physiologically relevant to activation of retinal guanylate cyclase, inhibition at high concentrations
ATP
-
ATP binding to the allosteric site is essential for the activation of isoform GC-B under physiologic condition. ATP increases the activities 2.4fold for isoform GC-A and 1.4fold for isoform GC-B
ATP
-
ATP-binding pocket and second, the transduction region, structure modelling, overview. The binding pocket resides in the smaller, N-terminal lobe of the ARM and the transduction region in the larger, predominantly helical, C-terminal lobe, overview. ATP-dependent mode of ANF-RGC signal transduction mechanism
ATP
-
induces a concentration-dependent increase in basal and atrial natriuretic peptide 1-28-stimulated GC activity of glomerular and papillary membranes that is significantly higher in spontaneously hypertensive rats than in age-matched Wistar Kyoto rats
atrial natriuretic peptide
-
activation of the particulate form
-
atrial natriuretic peptide
-
-
-
atrial natriuretic peptide
-
activation of isoforms GC-A and GC-B
-
atrial natriuretic peptide
-
-
-
atrial natriuretic peptide
-
-
atrial natriuretic peptide
-
highly effective in stimulating cGMP production in MA-10 cells
-
atrial natriuretic peptide
-
activation of isoforms GC-A and GC-B
-
atrial natriuretic peptide
-
-
-
atrial natriuretic peptide
-
activation of isoforms GC-A and GC-B
-
atrial natriuretic peptide
-
increases cGMP production up to 300fold
-
BAY 41-2272
-
-
BAY 41-2272
-
allosteric activator
BAY 41-2272
-
one molecule is required for maximal enzyme activation and is tightly associated with sGC
BAY 41-2272
-
the addition of the effector to CO-activated enzyme causes the original 6-coordinate CO-heme to convert to an end product that is an equimolar mixture of a 5- and a new 6-coordinate CO-heme
BAY 41-2272
-
stimulator of the NO-independent, heme-dependent soluble guanylate cyclase, acts independently of and in synergism with NO producing anti-aggregatory, anti-proliferative, and vasodilatory effects, overview
BAY 41-2272
-
3-(4-amino-5-cyclopropylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine, synergistic activator of sGC
BAY 41-2272
-
heme-dependent sGC activator
BAY 41-2272
-
sGC stimulator
BAY 41-2272
-
riociguat, allosteric stimulator
BAY 41-2272
-
a soluble guanylyl cyclase stimulator, it attenuates ischemia/reperfusion phorbol-12-myristate-13-acetate-induced lung injury by interfering with the activation NADPH oxidases
BAY 41-2272
-
i.e. 5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine
BAY 41-2272
is effective against pulmonary hypertension in an ovine model
BAY 41-2272
-
sGC stimulant, relaxes newborn, but not adult bronchial muscle
BAY 41-2272
-
a direct sGC activator
BAY 41-2272
-
an allosteric activator
BAY 41-2272
-
is effective against pulmonary hypertension in a rat model
BAY 41-8543
-
-
BAY 41-8543
-
lowers blood pressure in normotensive dogs
BAY 41-8543
-
stimulator of the NO-independent, heme-dependent soluble guanylate cyclase, acts independently of and in synergism with NO producing anti-aggregatory, anti-proliferative, and vasodilatory effects, overview
BAY 41-8543
-
i.e. 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)pyrimidine-4,6-diamine, a sGC stimulator
BAY 41-8543
-
lowers blood pressure in normotensive rats
BAY 58-2667
-
-
BAY 58-2667
-
improves cardiac output accompanied with a drop in mean arterial pulmonary artery, right atrial, and pulmonary wedge pressure
BAY 58-2667
-
activates the NO- and haem-independent soluble guanylate cyclase, the compound is capable of selectively activating the oxidized/haem-free enzyme via binding to the enzyme's haem pocket, causing pronounced vasodilatation
BAY 58-2667
-
relaxes mesocolon specimen of type 2 diabetic patients, and induces potent arterial and venous vasodilation in patients with heart failure
BAY 58-2667
-
cinaciguat, a soluble guanylate cyclase activator
BAY 58-2667
-
cinaciguat, sGC activator
BAY 58-2667
inhaled as microparticles, it is effective in eliciting pulmonary vasodilation in lambs
BAY 58-2667
-
long term treatment causes a slight decrease in systolic blood pressure
BAY 58-2667
-
activates the heme-free sGC 200fold, the activation is increased by inhibitor 1H-[1,2,4]oxidazolol[4,3a]quinoxalin-1-one
BAY 60-2770
-
activator BAY 60-2770 has higher efficiency on the purified protein than BAY 58-2667, i.e. cinaciguat
BAY 60-2770
-
i.e. 4-([(4-carboxybutyl)[2-(5-fluoro-2-([4'-(trifluoromethyl)biphenyl-4-yl]methoxy)phenyl)ethyl]amino]methyl)benzoic acid, NO-independent activation, the compound attenuates pig serum-induced liver fibrosis in vivo but does not affect blodd pressure in spontaneously hypertensive rats, overview
BaY 63-2521
-
a heme-dependent stimulator of sGC
BaY 63-2521
-
i.e. methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-ylmethylcarbamate, analysis of safety, tolerability, pharmacokinetics, and pharmacodynamics and pharmacodynamic effects of the compound, which is beneficial in reduction of blood pressure, overview
BaY 63-2521
-
i.e. methyl-4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimindin-5-ylmethylcarbamate, stimulates sGC directly and sensitizes it to NO, causes enzyme upregulation in pulmonary arterial hypertension lungs
BaY 63-2521
-
stimulator of the NO-independent, heme-dependent soluble guanylate cyclase, acts independently of and in synergism with NO producing anti-aggregatory, anti-proliferative, and vasodilatory effects, overview
BaY 63-2521
-
i.e. methyl-4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimindin-5-ylmethylcarbamate, stimulates sGC directly and sensitizes it to NO, causes enzyme upregulation in pulmonary arterial hypertension lungs
BaY 63-2521
-
i.e. methyl-4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimindin-5-ylmethylcarbamate, stimulates sGC directly and sensitizes it to NO, causes enzyme upregulation in pulmonary arterial hypertension lungs
brain natriuretic peptide
-
activation of isoforms GC-A and GC-B
-
brain natriuretic peptide
-
highly effective in stimulating cGMP production in MA-10 cells
-
brain natriuretic peptide
-
activation of isoforms GC-A and GC-B
-
brain natriuretic peptide
-
activation of isoforms GC-A and GC-B
-
C-type natriuretic peptide
-
-
-
C-type natriuretic peptide
-
activation of isoforms GC-A and GC-B
-
C-type natriuretic peptide
-
activation of isoforms GC-A and GC-B
-
C-type natriuretic peptide
-
-
-
C-type natriuretic peptide
-
activation of isoforms GC-A and GC-B
-
cGMP
-
activation
cinaciguat
-
i.e. 4-([(4-carboxybutyl)[2-(2-[[4-(2-phenylethyl)benzyl]oxy]phenyl)ethyl]amino]methyl) benzoic acid or BAY 58-2667, analysis of safety, tolerability, pharmacokinetics, and pharmacodynamics of cinaciguat in treatment of patients with heart failure, the agent induces vasodilation preferentially in diseased vessels, overview
cinaciguat
-
i.e. BAY 58-2667. Activator BAY 60-2770 has higher efficiency on the purified protein than BAY 58-2667
cinaciguat
-
cinaciguat activates the heme-free enzyme in a concentration-dependent manner with an EC50 value of about 0.2 microM and maximal cGMP formation at 10 microM. The compound causes time- and concentration-dependent relaxation of precontracted vessels with a maximal effect observed at 90 minutes. The dilatory response is not affected by extensive washout of the drug. Cinaciguat-induced vasodilation is associated with a time- and concentration-dependent increase of cGMP levels. The effect of cinaciguat on 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one-oxidized (ferric) soluble guanylate cyclase is moderate, reaching about 10%-15% of maximal activity
CO
-
-
CO
-
ferrous soluble guanylate cyclase binds CO as two reversible steps. The primary step leads to the full conversion of the ferrous enzyme to the 6-coordinate CO-heme, followed by the slower second step leading to a partial conversion of the 6-coordinate CO-heme to the 5-coordinate CO-heme. Reaction may folow a multistep mechanism, in which the 5-coordinate CO-heme is led by CO release from a putative bis-carbonyl intermediate that is likely provided by the binding of a second CO to the 6-coordinate CO-heme
CO
-
2fold activation in absence of 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole, 115fold activation in presence of 0.15 mM 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole
cone-specific calcium sensor guanylate cyclase activating protein 4
-
encoded by gene zGCAP4 from zebrafish, cloning and expression in Escherichia coli, zGCAP4 is a strong activator of membrane-bound guanylate cyclases from bovine retina, mainly present as a monomer and showing half-maximal activation at 520-570 nM free Ca2+ concentration
-
cone-specific calcium sensor guanylate cyclase activating protein 4
-
encoded by gene zGCAP4 from zebrafish, cloning and expression in Escherichia coli, zGCAP4 is a strong activator of membrane-bound guanylate cyclases from zebrafish retina, mainly present as a monomer and showing half-maximal activation at 520-570 nM free Ca2+ concentration
-
G protein alpha subunit
-
-
-
G protein alpha subunit
-
-
-
G protein alpha subunit
-
-
-
G protein alpha subunit
-
-
-
G protein alpha subunit
-
-
-
G protein alpha subunit
-
-
G protein alpha subunit
-
-
-
G protein alpha subunit
-
-
-
GTPgammaS
-
increases activity to 58%
GTPgammaS
-
activates by reducing the Km for GTP
GTPgammaS
-
stimulates activity of guanylyl cyclase GCA by lowering the KM-value of GTP and increasing the Vmax, half-maximal stimulation at 0.011 mM
GTPgammaS
-
stimulates activity of soluble guanylyl cyclase (sGC) by lowering the KM-value of GTP and increasing the Vmax, half-maximal stimulation at 0.008 mM
GTPgammaS
-
activates by reducing the Km for GTP, half-maximal activation at 0.008 mM
guanylin
-
activation of isoform GC-C
guanylin
-
activation of isoform GC-C
HMR-1766
-
stimulates the enzyme, especially heme-free sGC, identification of the interaction region and binding structure of the enzyme by computational modelling
HMR-1766
-
chronic treatment causes reduced ex-vivo platelet adhesion and in vivo vasodilator-stimulated phosphoprotein phosphorylation
HMR-1766
-
causes long-lasting decrease in systolic blood pressure
hydrogencarbonate
ED50 value of 27 mM. Stimulation is more powerful in the presence of activating protein GCAP1 or GCAP2 at low concentrations of Ca2+
hydrogencarbonate
ED50 value of 39 mM. When applied to retinal photoreceptors, hydrogencarbonate enhances the circulating current, decreases sensitivity to flashes, and accelerates flash response kinetics
natriuretic peptide
-
-
-
natriuretic peptide
-
-
-
natriuretic peptide
-
-
-
natriuretic peptide
-
-
-
natriuretic peptide
-
the transcription factor Ets-1 regulates the natriuretic peptide receptor-A gene expression and the stimulation of the guanylate cyclase GC-A isozyme
-
natriuretic peptide
-
-
-
natriuretic peptide
-
-
-
natriuretic peptide
-
-
-
nitric oxide
-
-
nitric oxide
-
stimulates activity if sGC, 2.2 nM thrombospondin-1 binds to CD47 and potently inhibits nitric oxide stimulation of sGC
nitric oxide
stimulates cyclase activity
nitric oxide
-
nitric oxide binds to its receptor soluble guanylyl cyclase and leads to 3',5'-cyclic-GMP production
NO
-
-
NO
-
perfect heme ligand, serves as an effector of enzyme activation via conformational transitions
NO
-
about 5000fold activation over basal level, mechanism for NO receptor activation and its modulation by GTP, ATP, and allosteric agents, model formation comprising a module in which NO, the nucleotides, and allosteric agents bind and the protein undergoes a conformational change, dovetailing with a catalytic module where GTP is converted to cGMP and diphosphate, enzyme-linked receptor mechanism, overview
NO
-
activates the soluble guanylyl cyclase
NO
-
activation of sGC by NO, released from 2,2-diethyl-1-nitroso-oxyhydrazine, is a link to the nitroglycerin biotransformation by mitochondrial aldehyde dehydrogenase, ALDH2
NO
-
binding of NO to a regulatory heme group at the beta-subunit of the protein results in 100fold stimulation of cGMP formation, NO is involved in the vascular NO/cGMP signalling, dysfunction of the signaling is thought to contribute to a wide variety of cardiovascular disorders
NO
-
the enzyme activation by NO leads to increased pulmonary artery relaxation, the activation is inhibited by heme depletion through heme oxygenase-1 induction
NO
-
interacts with the heme cofactor via the heme NO oxygen domain, structural basis, thermodynamics, and kinetics, activation mechanism involving the alphaFbeta1 loop in the iron proximal histidine bond breaking process, overview
NO
-
nitric oxide-sensitive guanylate cyclase
NO
-
H-NOX has a very high affinity for NO, with a Kd in the femtomolar range, NO complex wiht H-NOX is very stable, five-coordinate NO complex
NO
-
induces vasorelaxation
NO
-
conventional isoforms Gyca-99B and Gycb-100B are potently activated by NO. Atypical sGCs Gyc-88E Gyc-89Da Gyc-89Db are only slightly sensitive to NO. At atmospheric O2 concentrations, NO slightly stimulates the Gyc-88E+Gyc-89Da and Gyc-88E+Gyc-89Db subunit combinations, whereas at lower O2 concentrations NO inhibits their activity
NO
-
sGC activity increases 8fold upon binding of NO
NO
-
perfect heme ligand, serves as an effector of enzyme activation via conformational transitions
NO
-
activates the soluble guanylate cyclase, the activation is abolished by 1H-[1,2,4]oxadiazolo[4.3a]quinoxalin-1-one
NO
-
nitric oxide is a modulator of neurotransmission in cardiac ganglia and in neural control of the adult human heart
NO
-
NO-activated soluble guanylyl cyclase
NO
-
physiologic stimulator
NO
NO stimulates elevation of endogenous cGMP in Pharbitis nil, which allows for stimulation of flower bud formation in non-inductive conditions
NO
-
is bound in the distal heme pocket of the L2 H-NOX fold, NO dissociates from the distal side of the heme in both 5- and 6-coordinate complexes
NO
170fold activation, binding of NO leads to a transient six-coordinate intermediate, followed by release of the proximal histidine to yield a five-coordinate nitrosyl complex. Hallmark of sGC activation by NO is the release of beta1 His105 from the heme, leading to allosteric stimulation of cyclase activity
NO
-
activates the sGCalpha2beta1 enzyme and induces muscle relaxation after electric field stimulation
NO
-
NO, acting via isozyme sGCalpha1beta1, is the principal neurotransmitter in electrical field stimulation-evoked responses
NO
-
physiologic stimulator
NO
-
NO-activated soluble guanylyl cyclase
NO
-
is bound in the distal heme pocket of the L2 H-NOX fold, NO dissociates from the distal side of the heme in both 5- and 6-coordinate complexes
NO
-
binds at beta1 subunit heme, several hundred fold increase in activity
NO
-
127fold activation in absence of 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole, 211fold activation in presence of 0.15 mM 3-(5'-hydroxymethyl-3'-furyl)-1-benzylimidazole
NO
-
binds to the heme cofactor in the beta1 subunit, forming a five-coordinate NO complex that activates the enzyme several hundred-fold
NO
-
NO binds to the heme of soluble guanylate cyclase heme, activating the enzyme. In the presence of physiological concentrations of ATP and GTP, NO dissociation from the heme of soluble guanylate cyclase is about 160 times slower than the rate of enzyme deactivation in vitro. Deactivated enzyme still has NO bound to the heme, and full activation requires additional NO. An activation model is proposed where, in the presence of both ATP and GTP, tonic NO forms a stable heme complex with low activity, acute production of NO transiently and fully activates this NO-bound enzyme
NO
-
beta2 homodimer forms a five-coordinate Fe(II)-NO-complex
NO
-
binding of NO to sGC leads to the formation of a five-coordinate ferrous-nitrosyl complex and a several hundred-fold increase in cGMP synthesis, the NO activation of sGC is influenced by GTP and the allosteric activators YC-1 and BAY 41-2272, analysis of the Fe-NO conformation, overview
NO
-
binds and activates the enzyme
NO
-
NO indirectly inhibits 5-lipoxygenase metabolism synthesis via activation of soluble guanylyl cyclase in rat alveolar macrophages
NO
-
physiologic stimulator
NO
-
the sensitivity to NO is increased in case of obesity and high-fat diet
NO
-
activates the soluble guanylate cyclase, the activation is abolished by 1H-[1,2,4]oxadiazolo[4.3a]quinoxalin-1-one
O2
-
-
O2
-
H-NOX forms/does not form a stable O2 complex at 70°C, diverging studies
O2
-
atypical sGCs potently activated under hypoxic conditions
protoporphyrin IX
-
0.001 mM activates untreated sGC with around half the effectiveness of nitric oxide
S-nitrosocysteine
-
induces vasorelaxation through release of NO, and causes reversible S-nitrosylation of sGC and desensitization in primary aortic smooth muscle cells, which is prevented by N-acetylcysteine
S-nitrosocysteine
-
activates soluble guanylyl cyclase at low concentration (0.02 mM), oxy-hemoglobin inhibits the ability of S-nitrosocysteine to activate sGC
sodium nitroprusside
-
-
sodium nitroprusside
-
activation of the soluble form
sodium nitroprusside
-
synergistic to YC-1 and A-350619 for the binding site
sodium nitroprusside
-
synergistic to YC-1 and A-350619 for the binding site
sodium nitroprusside
0.1 mM, 580fold stimulation, NO donor
sodium nitroprusside
-
NO donor
sodium nitroprusside
-
synergistic to YC-1 and A-350619 for the binding site
sodium nitroprusside
via NO production
sodium nitroprusside
-
synergistic to YC-1 and A-350619 for the binding site
sodium nitroprusside
-
synergistic to YC-1 and A-350619 for the binding site
sodium nitroprusside
synergistic to YC-1 and A-350619 for the binding site
sodium nitroprusside
-
activation of the soluble form
sodium nitroprusside
-
NO donor
sodium nitroprusside
-
NO donor, significant higher stimulation of sGC activity in newborns compared with adults
sodium nitroprusside
activates via release of NO
sodium nitroprusside
-
an NO donor
sodium nitroprusside
-
synergistic to YC-1 and A-350619 for the binding site
sodium nitroprusside
-
synergistic to YC-1 and A-350619 for the binding site, 230fold activation in presence of A-350619
Triton X-100
-
activation
Triton X-100
-
activation
von Willebrand factor/ristocetin
-
increases the enzyme activity in an NO-independent manner correlating with Src kinase-dependent phosphorylation of sGC beta1-subunit-Tyr192
-
von Willebrand factor/ristocetin
-
increase the enzyme activity in an NO-independent manner correlating with Src kinase-dependent phosphorylation of sGC beta1-subunit-Tyr192
-
YC-1
-
allosteric activator
YC-1
-
synergistic with NO, blocked by 1H-[1,2,4]oxidazolol[4,3a]quinoxalin-1-one
YC-1
-
synergistic with NO, blocked by 1H-[1,2,4]oxidazolol[4,3a]quinoxalin-1-one
YC-1
-
stimulator of the NO-independent, heme-dependent soluble guanylate cyclase, acts independently of and in synergism with NO producing anti-aggregatory, anti-proliferative, and vasodilatory effects, overview
YC-1
-
synergistic with NO, blocked by 1H-[1,2,4]oxidazolol[4,3a]quinoxalin-1-one
YC-1
-
heme-dependent sGC activator
YC-1
-
allosteric stimulator
YC-1
affects binding of NO and CO to the enzyme, it reduces the NO and CO off-rates for the 100 kDa N-terminal heterodimeric fragment and increases the CO affinity by 50fold, overview
YC-1
-
i.e. 1-benzyl-3-(5'-hydroxymethyl-2'-furyl-)-indazol, a sGC sensitizer, able to potentiate CO- and CORM-2-induced relaxations in wild-type mice
YC-1
-
synergistic with NO, blocked by 1H-[1,2,4]oxidazolol[4,3a]quinoxalin-1-one
YC-1
-
an NO-independent activator of sGC
YC-1
-
synergistic with NO, blocked by 1H-[1,2,4]oxidazolol[4,3a]quinoxalin-1-one
YC-1
-
activator of soluble guanylyl cyclase
YC-1
synergistic with NO, blocked by 1H-[1,2,4]oxidazolol[4,3a]quinoxalin-1-one
YC-1
-
sGC stimulant, relaxes newborn, but not adult bronchial muscle
YC-1
-
a non-NO-dependent activator of sGC
YC-1
-
an allosteric activator
YC-1
-
synergistic with NO, blocked by 1H-[1,2,4]oxidazolol[4,3a]quinoxalin-1-one
YC-1
-
synergistic with NO, blocked by 1H-[1,2,4]oxidazolol[4,3a]quinoxalin-1-one, from rats, synergistic to A-350619 and sodium nitroprusside for the binding site, 160fold activation in presence of A-350619
additional information
-
insensitive to NO
-
additional information
-
insensitive to NO
-
additional information
-
insensitive to NO
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
insensitive to NO
-
additional information
-
no affinity for O2, the mechanism of oxygen exclusion by sGC not only involves the lack of hydrogen bonding in the distal heme pocket, but also depends on structural elements from other domains of sGC
-
additional information
-
the nitric oxide system is an activator of renal soluble GC
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
guanylate cyclase activation mechanism, overview
-
additional information
-
guanylate cyclase activation mechanism, overview
-
additional information
-
no nitrosylating and activating effect by S-nitrosoglutathione
-
additional information
-
electrical field stimulation partially activates the enzyme and induces smooth muscle relaxation, overview
-
additional information
-
none of the atypical sGCs are activated by the NO-independent, but heme-dependent, sGC stimulator BAY 41-2272
-
additional information
-
insensitive to NO
-
additional information
-
GCC is activated by diarrheagenic bacterial heat-stable enterotoxins, which suppress proliferation of Caco-2 human colon carcinoma cells. Exisulind inhibits the ability of diarrheagenic bacterial heat-stable enterotoxin to induce maximal intracellular cGMP accumulation
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
identification of stimulating acryl-amide compounds, that act independently of YC-1 stimulators and promote smooth muscle relaxation
-
additional information
-
synthesis of STa, exogenous heat-stable enterotoxin, fragments peptide 3 and peptide 6, which behave as agonists in stimulating cGMP production, overview
-
additional information
-
neither staurosporine nor Go6976 activate isoforms GC-A or GC-B
-
additional information
sGC is influenced by the light conditions, overview
-
additional information
-
sGC is influenced by the light conditions, overview
-
additional information
insensitive to NO stimulation, bovine calmodulin fails to stimulate the enzyme
-
additional information
-
insensitive to NO stimulation, bovine calmodulin fails to stimulate the enzyme
-
additional information
soluble guanylyl cyclase beta-3 subunit responds poorly to nitric oxide
-
additional information
-
soluble guanylyl cyclase beta-3 subunit responds poorly to nitric oxide
-
additional information
-
insensitive to NO
-
additional information
for maximal activity, msGC required both NO and YC-1
-
additional information
-
for maximal activity, msGC required both NO and YC-1
-
additional information
-
C-type natriuretic peptide does not stimulate cGMP production
-
additional information
-
direct stimulation of cGMP synthesis and activation of mitogen-activated protein kinase signaling pathways underlies the capacity of Mn2+ to augment NF-kappaB-dependent gene expression in astrocytes
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
NO-independent sGC activation is synergistic with NO-sGC stimulation
-
additional information
-
synthesis of STa, exogenous heat-stable enterotoxin, fragments peptide 3 and peptide 6, which behave as agonists in stimulating cGMP production, overview
-
additional information
treatment of mice with angiotensin II results in enhanced pulmonary mRNA expression of spliced GC-A, which is concomitant to diminished GC-A/cGMP responses to atrial natriuretic peptide, overview
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
C-type natriuretic peptide does not stimulate cGMP production
-
additional information
-
guanylin is totally ineffective in stimulating ONE-GC
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
soluble GC alpha-1 and beta-1 subunit mRNA levels are increased in the lungs, but not in the aorta in a sepsis model, overview
-
additional information
soluble GC alpha-1 and beta-1 subunit mRNA levels are increased in the lungs, but not in the aorta in a sepsis model, overview
-
additional information
-
tirofiban, which mimics the structure of arginine-glycine-aspartic acid peptides, up-regulates soluble guanylate cyclase beta1 subunit, sGC-beta1, expression in contractile vascular smooth muscle cells and in aorta from rats, and tirofiban reverses the down-regulation of soluble guanylate cyclase content promoted by chronic treatment with NO donors and NO donor tachyphylaxis
-
additional information
-
effects of activators and inhibitors on enzyme regulation, overview
-
additional information
-
NO treatment elevates the enzyme activity shortly after application, but does not significantly affect the steady-state levels of cGMP
-
additional information
-
insensitive to NO
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0357
2'-O-(N-methylanthraniloyl) guanosine 5'-triphosphate
-
-
0.37
guanyl-(beta,gamma-methylene)-diphosphonate
-
-
0.07
guanyl-imidodiphosphate
-
-
additional information
additional information
-
0.01
GTP
-
-
0.021
GTP
-
pH 8.0, 30°C, wild-type enzyme, in presence of NO-donor S-nitroso-N-acetylpenicillamine
0.025
GTP
-
30°C, pH 8.0, in the presence of N-(beta-D-glucopyranosyl-N2-acetyl-S-nitroso-D,L-penicillaminamide) and YC-1
0.039
GTP
-
30°C, pH 8.0, in the presence of YC-1
0.043
GTP
purified recombinant sGC in presence of 3-ethyl-3-(ethylaminoethyl)-1-hydroxy-2-oxo-1-triazene
0.0498
GTP
-
pH 7.5, 37°C, NO-stimulated recombinant enzyme
0.054
GTP
wild-type, 37°C, temperature not specified in the publication, pH not specified in the publication
0.057
GTP
-
in the presence of NO
0.061
GTP
-
30°C, pH 8.0, in the presence of N-(beta-D-glucopyranosyl-N2-acetyl-S-nitroso-D,L-peniciiaminamide)
0.065
GTP
recombinant sGC
0.069
GTP
-
in the absence of Ca2+ and in the presence of 0.05 mM nitric oxide, in 50 mM HEPES, pH 7.5, at 37°C
0.07
GTP
-
octylglucoside solubilized enzyme, Mn2+-supported enzyme
0.07
GTP
mutant S502A, temperature not specified in the publication, pH not specified in the publication
0.074
GTP
-
at the basal state of sGC
0.088
GTP
mutant S473A, temperature not specified in the publication, pH not specified in the publication
0.0901
GTP
-
pH 7.5, 37°C, not stimulated recombinant enzyme
0.099
GTP
mutant S487A, temperature not specified in the publication, pH not specified in the publication
0.1
GTP
alpha2,beta1 isoform
0.107
GTP
mutant T500E, temperature not specified in the publication, pH not specified in the publication
0.111
GTP
mutant T513E, temperature not specified in the publication, pH not specified in the publication
0.113
GTP
mutant S502E, temperature not specified in the publication, pH not specified in the publication
0.116
GTP
mutant S473E, temperature not specified in the publication, pH not specified in the publication
0.12
GTP
-
30°C, pH 8.0, basal activity
0.122
GTP
-
pH 8.0, 30°C, wild-type enzyme
0.134
GTP
-
37°C, pH 7.4, recombinant sGC
0.14
GTP
-
native enzyme, Mn2+-supported enzyme
0.144
GTP
mutant S487E, temperature not specified in the publication, pH not specified in the publication
0.15
GTP
mutant T500A, temperature not specified in the publication, pH not specified in the publication
0.16
GTP
-
37°C, pH 7.5, in the absence of ATP
0.162
GTP
mutant S510E, temperature not specified in the publication, pH not specified in the publication
0.165
GTP
mutant T513A, temperature not specified in the publication, pH not specified in the publication
0.18
GTP
purified recombinant sGC
0.184
GTP
mutant S497E, temperature not specified in the publication, pH not specified in the publication
0.19
GTP
-
in the absence of NO
0.195
GTP
mutant S510A, temperature not specified in the publication, pH not specified in the publication
0.196
GTP
mutant S506E, temperature not specified in the publication, pH not specified in the publication
0.221
GTP
mutant S506A, temperature not specified in the publication, pH not specified in the publication
0.234
GTP
-
in the absence of Ca2+ and nitric oxide, in 50 mM HEPES, pH 7.5, at 37°C
0.25
GTP
-
guanylyl cyclase GCA
0.36
GTP
-
37°C, pH 7.5, in the presence of 1 mM ATP
0.386
GTP
purified enzyme
0.389
GTP
mutant S497A, temperature not specified in the publication, pH not specified in the publication
0.4
GTP
-
native enzyme, Mg2+-supported enzyme
0.401
GTP
-
octylglucoside solubilized enzyme, Mg2+-supported enzyme
0.4077
GTP
-
Wistar Kyoto rats, in presence of atrial natriuretic peptide 1-28 and ATP in glomerular membranes
0.414
GTP
-
soluble guanylyl cyclase sGC
0.455
GTP
recombinant enzyme
0.5597
GTP
-
Wistar Kyoto rats, in presence of atrial natriuretic peptide 1-28 in glomerular membranes
0.63
GTP
-
isozyme RetGC2, stimulated by guanylyl cyclase activating protein 1,in 30 mM MOPS-KOH (pH 7.2), 60 mM KCl, 4 mM NaCl, 1 mM dithiothreitol, 2 mM Ca2+/EGTA buffer, at 30°C
0.64
GTP
-
isozyme RetGC1, stimulated by guanylyl cyclase activating protein 1, in 30 mM MOPS-KOH (pH 7.2), 60 mM KCl, 4 mM NaCl, 1 mM dithiothreitol, 2 mM Ca2+/EGTA buffer, at 30°C
0.66
GTP
-
with 0.273 mM oxygen
0.667
GTP
-
Wistar Kyoto rats, in presence of ATP in glomerular membranes
0.7
GTP
-
isozyme RetGC1, stimulated by guanylyl cyclase activating protein 2, in 30 mM MOPS-KOH (pH 7.2), 60 mM KCl, 4 mM NaCl, 1 mM dithiothreitol, 2 mM Ca2+/EGTA buffer, at 30°C
0.752
GTP
-
particulate form
0.79
GTP
-
isozyme RetGC2, stimulated by guanylyl cyclase activating protein 2,in 30 mM MOPS-KOH (pH 7.2), 60 mM KCl, 4 mM NaCl, 1 mM dithiothreitol, 2 mM Ca2+/EGTA buffer, at 30°C
0.82
GTP
-
under anaerobic conditions
0.8234
GTP
-
Wistar Kyoto rat, basal GC activity of glomerular membranes
0.857
GTP
-
in the presence of 2 mM Ca2+ and in the absence of nitric oxide, in 50 mM HEPES, pH 7.5, at 37°C
0.887
GTP
-
in the presence of 2 mM Ca2+ and 0.05 mM nitric oxide, in 50 mM HEPES, pH 7.5, at 37°C
1.55
GTP
-
nonstimulated isozyme RetGC1, in 30 mM MOPS-KOH (pH 7.2), 60 mM KCl, 4 mM NaCl, 1 mM dithiothreitol, 2 mM Ca2+/EGTA buffer, at 30°C
2.16
GTP
-
pH 7.5, 22°C, wild-type enzyme, wild-type enzyme
3.18
GTP
-
nonstimulated isozyme RetGC2, in 30 mM MOPS-KOH (pH 7.2), 60 mM KCl, 4 mM NaCl, 1 mM dithiothreitol, 2 mM Ca2+/EGTA buffer, at 30°C
5.78
GTP
pH 7.5, 22°C, wild-type enzyme, wild-type enzyme
6.09
GTP
pH 7.5, 22°C, wild-type enzyme, mutant enzyme E497K/C566D
additional information
additional information
-
activation kinetics and thermodynamics, binding of GTP and NO, overview
-
additional information
additional information
kinetics of ligand binding
-
additional information
additional information
-
kinetics of ligand binding
-
additional information
additional information
kinetics, purified recombinant sGC, overview
-
additional information
additional information
kinetics, purified recombinant sGC, overview
-
additional information
additional information
-
kinetics, purified recombinant sGC, overview
-
additional information
additional information
the soluble enzyme has two active sites in the dimer exhibiting positive cooperativity with a Hill coefficient of about 1.5
-
additional information
additional information
-
the soluble enzyme has two active sites in the dimer exhibiting positive cooperativity with a Hill coefficient of about 1.5
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
-
-
brenda
-
-
brenda
-
-
brenda
-
brain natriuretic peptide stimulated membrane-bound GC
brenda
-
2-4 months old
brenda
-
-
brenda
-
prominent for beta1 and to a lesser extent for the other subunits
brenda
-
high expression of beta1 and moderate to low expression of both alpha subunits
brenda
-
-
brenda
-
coronary
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
atypical sGC primarily expressed
brenda
co-expression of both alpha and beta subunits of NO-sensitive sGC
brenda
-
-
brenda
-
the guanylyl cyclase messenger system is potentially responsive to hormones/neurotranmitters that may control the degree of relaxation in this vascular tissue
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
vascular
brenda
-
-
brenda
-
lower esophageal sphincter circular smooth muscle
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
high levels of alpha2, and moderate levels of alpha1 and beta1 in the lateral amygdaloid nucleus. In the hippocampal formation the presence of alpha1 and alpha2 mRNA is higher in the dentate gyrus and in the presubiculum and lower in the different CA subfields, beta1 mRNA particularly enriched in the hippocampal fields. In the hilus, large neurons contain significantly higher levels of beta1 and alpha2
brenda
-
-
brenda
low enzyme content
brenda
-
expression of the beta1 subunit moderate in the ventromedial, dorsomedial, arcuate, and geniculate nuclei. In these hypothalamic nuclei levels for the alpha subunits are low, all three subunits show moderate levels in the interpeduncular nucleus
brenda
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
in the anterior region expression of atypical sGCs in sensory neurons that innervate the dorsal and terminal organs, believed to be the main chemosensory organs of the larvae. Along the lateral body wall of larvae expressed by individual sensory neurons that express each of the subunits that appear to innervate basiconic sensilla and trachea. In the terminal segments, atypical sGCs are expressed in neurons that innervate peg sensilla on the caudal sensory cones
brenda
-
-
brenda
-
sGC alpha2 and beta1 subunits expressed strongly by dentate gyrus granule cells and CA1-CA3 pyramidal neurons, expression of alpha1 mRNA is high in CA2 pyramidal cells but low in the other CA subfields
brenda
-
expression of alpha1 and beta1 subunits of sGC
brenda
-
-
brenda
-
alveolar
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
brenda
-
brain- and atrial natriuretic peptide stimulated membrane-bound GC
brenda
-
-
brenda
-
high expression of beta1 and moderate to low expression of both alpha subunits
brenda
-
isozyme GC-D is exclusively expressed in the olfactory neuroepithelium in rodents
brenda
-
the membrane guanylate cyclase is exclusively expressed in the CO2-responsive olfactory sensory neurons
brenda
-
brenda
-
-
brenda
-
-
brenda
-
adrenal medulla derived cell line
brenda
-
very low expression of alpha1 and beta1 subunits of sGC
brenda
-
-
brenda
-
-
brenda
-
atypical sGC primarily expressed
brenda
-
-
brenda
-
shows high levels of expression for beta1 mRNA and moderate for alpha1 and alpha2 mRNAs
brenda
-
anterior, sGC alpha2 inhibitory isoform and sGC alpha2 isoform are expressed
brenda
-
-
brenda
sGC protein enriched at the leading edge of the cell during chemotaxis
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
brenda
-
brenda
-
brenda
-
-
brenda
-
isozyme GC-G
brenda
-
expression of soluble guanylate cyclase is significantly higher in white vs. black sheep skin both at the mRNA and protein levels
brenda
-
upon development, mRNA expression of guanylyl cyclase GCA decreases about 5fold during aggregation and subsequently rises, reaching a maximum during the slug stage
brenda
-
upper villous and crypt cells
brenda
-
-
brenda
-
shows high expression of beta1, moderate of alpha2, and low of alpha1
brenda
-
moderate expression of beta1, alpha subunits expression is very low
brenda
-
atrial natriuretic peptide stimulated membrane-bound GC and guanylin-stimulated GC-C
brenda
-
colon cancer cell line
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
GC-B is the predominant functional membrane-bound guanylyl cyclase subtype
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
soluble guanylyl cyclase sGC is mainly expressed during aggregation phase
brenda
-
upon development, mRNA expression of guanylyl cyclase GCA decreases about 5fold during aggregation and subsequently rises, reaching a maximum during the slug stage
brenda
-
brenda
-
-
-
brenda
-
-
brenda
-
-
brenda
-
primary aortic smooth muscle cells
brenda
-
-
brenda
-
human aortic smooth muscle cells
brenda
-
-
brenda
-
-
brenda
-
brenda
-
-
brenda
-
brenda
-
aortic ring
brenda
-
vascular wall and smooth muscle cells
brenda
-
-
brenda
-
-
brenda
-
pulmonary
brenda
-
pulmonary
brenda
-
-
brenda
-
pulmonary
brenda
isozymes GC-A
brenda
-
-
brenda
-
pulmonary
brenda
-
isozymes GC-A
brenda
-
-
brenda
pulmonary
brenda
-
-
brenda
-
pulmonary
brenda
-
pulmonary, but not aorta
brenda
-
pulmonary
brenda
-
pulmonary, cultured model
brenda
-
coronary artery
brenda
-
-
brenda
-
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
beta1-subunit, alpha2-subunit not present
brenda
-
smooth muscle
brenda
-
-
brenda
-
beta1-subunit, alpha2-subunit not present
brenda
-
beta1-subunit, alpha2-subunit not present
brenda
-
-
brenda
-
alpha1 subunit most prominent
brenda
-
-
brenda
-
-
brenda
-
myelin
brenda
-
sGC beta1 is the most abundant and ubiquitous subunit
brenda
-
expression pattern of sGC in tissue form wild-type and spontaneously hypertensive rats, e.g. in rostral ventrolateral medulla, overview
brenda
-
-
brenda
-
-
brenda
-
mRNAs coding for all subunits high and homogeneously distributed
brenda
-
highest levels of mRNA for beta1, alpha1 and alpha2 subunits
brenda
-
alpha2-subunit most prominent in the molecular layer followed by the ganglionic layer, low amounts in the granular layer
brenda
-
alpha2-subunit most prominent in the molecular layer followed by the ganglionic layer, low amounts in the granular layer
brenda
-
mRNA coding for beta1 and alpha2 subunits is high in Purkinje cells, small cells located close to the Purkinje cells, probably Bergmann glia, contain high densities of alpha1 mRNA. The granule cell layer is enriched in beta1 mRNA and shows moderate levels for alpha2 and low for alpha1 mRNA. The medial and lateral inferior olive nuclei show intense levels of beta1
brenda
-
alpha2-subunit most prominent in the molecular layer followed by the ganglionic layer, low amounts in the granular layer
brenda
-
alpha2 and beta1 abundant in Purkinje cells, small cells close to Purkinje cells express high levels of alpha1 mRNA, alpha2 and beta1 expression very high and homogeneous in the granule cell layer
brenda
-
present at weaker levels
brenda
-
all neocortical areas with high expression of all subunits, expression of the three subunits in all cortical layers, alpha1 subunit enriched in layer VI
brenda
-
beta1 subunit mRNA widely distributed through all cortical areas and cell layers with higher intensity in layer V, alpha2 mRNA homogeneously distributed through all cortical layers and alpha1 expression higher in layers IIIII and V
brenda
-
low expression of all subunit mRNAs in many of the white matter tracts
brenda
-
moderate expression of alpha1 and alpha2 mRNAs in many white matter tracts, beta1 mRNA expression is very low
brenda
-
smooth muscle, low enzyme expression
brenda
-
-
brenda
-
distal
brenda
-
-
brenda
guanylyl cyclase C is a protein that is expressed in the cells that line the normal intestine and by metastatic colorectal cancer cells. Isozyme GCC is universally expressed by primary and metastatic colorectal tumors
brenda
-
guanylyl cyclase C is a protein that is expressed in the cells that line the normal intestine and by metastatic colorectal cancer cells. Isozyme GCC is universally expressed by primary and metastatic colorectal tumors
-
brenda
-
purified sGC from lung
brenda
-
dsRetGC1
brenda
-
-
brenda
-
-
-
brenda
isozyme GC-B
brenda
-
isozyme GC-B
brenda
isozyme GC-C
brenda
-
-
brenda
-
isozyme GC-C
brenda
-
-
-
brenda
-
brenda
-
brenda
-
retina and rod segements, retGC is a transmembrane protein localized in the outer segment
brenda
larval and adult eyes
brenda
-
-
brenda
-
anterior segment
brenda
retina and rod segements, retGC is a transmembrane protein localized in the outer segment
brenda
-
retina and rod segements, retGC is a transmembrane protein localized in the outer segment
brenda
-
-
brenda
-
anterior segment
brenda
eyestalk
brenda
-
cardiac, tissue localization, overview
brenda
-
brenda
-
dorsal root ganglion, NO-GC is restricted to non-neuronal cells in dorsal root ganglia
brenda
-
-
brenda
-
smooth muscle and myenteric layer
brenda
-
atrial- and C-type natriuretic peptide stimulated membrane-bound GC
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
at both tissue and single myocyte levels, sGC protein expression is heterogeneous, being high in sinoatrial node, right atrium, right ventricle and left ventricular subepicardium, but markedly reduced to absent in left atrium and left ventricular subendocardium
brenda
isozymes GC-A
brenda
-
-
brenda
-
isozymes GC-A
brenda
-
at both tissue and single myocyte levels, sGC protein expression is heterogeneous, being high in sinoatrial node, right atrium, right ventricle and left ventricular subepicardium, but markedly reduced to absent in left atrium and left ventricular subendocardium
brenda
-
-
brenda
-
brenda
-
-
brenda
-
from lean and obese rats, enzyme localization at left ventricle and coronary arteriole
brenda
-
-
brenda
-
right and left
brenda
-
right and left
brenda
-
-
brenda
isozyme GC-C
brenda
-
-
brenda
-
epithelium
brenda
guanylyl cyclase C is a protein that is expressed in the cells that line the normal intestine and by metastatic colorectal cancer cells
brenda
-
isozymes GC-C and GC-G
brenda
-
mucosal cell
brenda
-
epithelium
-
brenda
-
guanylyl cyclase C is a protein that is expressed in the cells that line the normal intestine and by metastatic colorectal cancer cells
-
brenda
-
-
brenda
-
brenda
GC-C
brenda
-
-
brenda
-
brenda
-
-
brenda
-
brenda
epithelial cells of the proximal tubule and collecting ducts
brenda
-
isozyme GC-G
brenda
-
-
brenda
-
C-type natriuretic peptide stimulated membrane-bound-GC
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
34833, 34850, 34857, 34858, 34866, 34869, 34874, 34879, 34881, 649442, 665511, 666248, 679399, 680671, 684348, 691656, 692446, 693082, 694270, 694411, 707918, 715597, 747134 brenda
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
brenda
-
isozyme GC-G
brenda
-
-
-
brenda
-
-
brenda
-
brenda
-
-
34838, 34851, 34856, 34877, 34878, 664098, 666731, 680895, 691072, 691541, 691656, 692204 brenda
-
brenda
-
GC-A activity is detected on mucus secreting globlet cells, Clara cells and grat alveolar cells
brenda
-
-
brenda
C57BL/6-derived colorectal cancer cells
brenda
-
C57BL/6-derived colorectal cancer cells
-
brenda
-
alpha1 subunit mRNA with restricted distribution in mesencephalic areas, moderate to high levels in the dorsal aspects of the periaqueductal gray, vestibular lateral and medial nuclei, and in prepositus hypoglossal nuclei, low alpha1 and alpha2 mRNA in the dorsal raphe nucleus, pedunculopontine tegmental nucleus, and oculomotor nuclei. Expression for alpha subunits pronounced in pontine nuclei
brenda
-
guanylyl cyclase-C protein is expressed predominantly on the somata and dendrites of dopaminergic neurons in the the midbrain ventral tegmental area and substantia nigra compacta
brenda
-
high levels of beta1 but low levels of alpha subunits in superior colliculus, locus coeruleus presents high levels of beta1 and alpha1 subunits, ventral tegmental nucleus wiht moderate levels of expression for the three sGC subunits
brenda
-
brenda
-
-
brenda
-
-
brenda
expressed specifically in the AFD thermosensory neurons
brenda
-
-
brenda
-
atypical sGC frequently co-localized in specific sensory neurons
brenda
the isozyme Gyc-89Da is encoded in neurons that are required for larval and adult ecdyses in the fruit fly
brenda
the isozyme Gyc-89Db is encoded in neurons that are required for larval and adult ecdyses in the fruit fly
brenda
-
-
brenda
-
brenda
-
midbrain dopamine neuron
brenda
-
-
brenda
-
present in the neurokinin 1 receptor-positive neurons in lamina I and many local circuit neurons in laminae I-II, expressed in most inhibitory interneurons
brenda
-
no co-localization of sGC with phenylethanolamine N-methyltransferase or tyrosine hydroxylase, or NO synthase in neurons
brenda
three membrane bound sensory guanylate cyclases, from developing and adult zebrafish retina
brenda
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina
brenda
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina
brenda
-
-
brenda
-
brenda
-
-
brenda
-
atrial natriuretic peptide stimulated membrane-bound GC
brenda
-
brenda
-
-
-
brenda
-
-
brenda
-
-
34832, 34836, 34841, 34852, 34860, 34861, 34863, 34870, 34876, 663886, 690841, 693267 brenda
-
brenda
-
soluble guanylate cyclase accounts for nearly 10% of the total guanylate cyclase activity of the retina
brenda
-
-
brenda
three membrane-bound sensory guanylate cyclases expressed in photoreceptor cells of the developing and adult zebrafish retina, expression analysis, overview
brenda
-
type 1 membrane-bound guanylate cyclase is expressed exclusively in the retina
brenda
-
-
brenda
-
brenda
isozyme GC-E
brenda
isozyme GC-F
brenda
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina
brenda
-
-
brenda
-
-
brenda
-
soluble guanylate cyclase accounts for nearly 20% of the total guanylate cyclase activity of the retina
brenda
-
isozymes GC-E and GC-F are colocalized within the same photoreceptor cells of the retina
brenda
-
-
-
brenda
-
present at high levels in inner retina but barely detectable in outer retina, ganglion cells exhibit moderate staining for sGC, strong immunostaining in subpopulations of bipolar and amacrine cells, weak staining in rod bipolar cells
brenda
natriuretic peptide-activated guanylate cyclase NPR-A is expressed in several layers of the retina including amacrine cells and the ganglion cell layer
brenda
natriuretic peptide-activated guanylate cyclase NPR-B is expressed in several layers of the retina including amacrine cells and the ganglion cell layer
brenda
-
-
brenda
-
ROS-GC1
brenda
-
-
brenda
-
-
-
brenda
-
-
brenda
-
gastrointestinal tract, muscularis mucosae and vasculature
brenda
-
tracheal and lung tissue smooth muscle
brenda
-
lower esophageal sphincter circular smooth muscle
brenda
-
pulmonary artery smooth muscle layer
brenda
-
-
brenda
-
pulmonary artery smooth muscle layer
brenda
-
gastrointestinal smooth muscle
brenda
-
-
brenda
-
protein expression of the alpha1- and beta1-sGC isoforms is significantly lower in the adult compared with the newborn bronchial tissue
brenda
gastrointestinal
brenda
-
pulmonary artery smooth muscle layer
brenda
-
vascular
brenda
-
primary aortic smooth muscle cells
brenda
-
-
brenda
-
vascular
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
predominantly expressed from round spermatids to spermatozoa in mouse testis at both the mRNA and protein levels
brenda
-
isozyme GC-G
brenda
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
NO-GC is distinctly expressed in neurons of the mouse dorsal horn
brenda
-
-
brenda
-
present at weaker levels
brenda
-
smooth muscle, low enzyme expression
brenda
-
gastrointestinal smooth muscle
brenda
-
brenda
-
detectable at day 18 of postnatal development and thereafter increasing progressively
brenda
-
-
brenda
-
many of the thalamic nuclei contain the three subunits, alpha1 and beta1 mRNA in both the anterior and posterior ventralis nuclei and in the pulvinar and reticular nuclei, alpha2 subunit mRNA is present at low levels in the pulvinar nucleus and barely detectable in other thalamic nuclei
brenda
-
high levels of mRNA for the three subunits in the medial habenula, in other thalamic nuclei mainly beta1 mRNA
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
brenda
-
-
brenda
-
-
brenda
abundance of the CsCG-YO1 transcript in Y-organs during a molt cycle: the level of CsGC-YO1 in Y-organs is elevated during intermolt, C4, and lower during premolt stages D1-D3
brenda
CsGC-YO1 transcript abundance during a molt cycle, overview
brenda
additional information
-
in Purkinje cell somata alpha2- and beta1-subunit present, alpha2-subunit not present in white matter
brenda
additional information
-
analysis of sGC in gastrointestinal tissue, immunohistochemic analysis
brenda
additional information
-
atypical sGC expressed throughout development
brenda
additional information
-
T84 cell and SW480 cell
brenda
additional information
-
heart tissue expression pattern, overview
brenda
additional information
-
no expression of alpha1 and beta1 subunits of sGC in DU-145 cells
brenda
additional information
tissue distribution, overview
brenda
additional information
-
tissue distribution, overview
brenda
additional information
-
in Purkinje cell somata alpha2- and beta1-subunit present, alpha2-subunit not present in white matter
brenda
additional information
-
no alpha subunits in the substantia nigra
brenda
additional information
-
in Purkinje cell somata alpha2- and beta1-subunit present, alpha2-subunit not present in white matter
brenda
additional information
-
not detectable in spermatogonia, Sertoli cells, and spermatocytes
brenda
additional information
-
GC-G has a broad tissue distribution in rodents
brenda
additional information
-
heart tissue expression pattern, overview
brenda
additional information
-
brainstem, subnucleus caudalis, where it is present in neuronal cell bodies in the superficial laminae and in astrocytes in deeper lamina
brenda
additional information
-
in cortex present at weaker levels, whereas photoreceptors, horizontal cells, Müller cells, and AII amacrine cells are immunonegative
brenda
additional information
-
in the superficial dorsal horn present throughout the gray matter, whereas unmyelinated primary afferent fibers terminating in the superficial dorsal horn lack sGC
brenda
additional information
-
newborn aged 25 days
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
?
-
x * 50300, His-tagged SUMO fusion protein, calculated from amino acid sequence
?
-
1 * 72000, SDS-PAGE after removal of carbohydrate residues
?
-
x * 70000 + x * 74000, SDS-PAGE
?
x * 130000, SDS-PAGE, x * 50000, recombinant isolated extracellular domain, SDS-PAGE, x * 51300, about, extracellular domain, sequence calculation
?
-
x * 21500, SDS-PAGE
-
?
-
x * 109000, isozyme RetGC2, SDS-PAGE
?
-
x * 112000, isozyme RetGC1, SDS-PAGE
dimer
2 * 130000, SDS-PAGE, 2 * 124000, about, sequence calculation
dimer
-
structural domains include the extracellular domain, kinase-like domain, and guanylate cyclase domain, molecular modelling, overview
dimer
-
2 * 72000, SDS-PAGE
dimer
-
alpha,beta 1 * 74000 + 1 * 69000, SDS-PAGE
dimer
1 * 77532, alpha subunit, + 1 * 70500, beta subunit, SDS-PAGE
dimer
-
the soluble guanylyl cyclase forms a heterodimer
dimer
catalytic domain, crystal structure, structure analysis and comparison, e.g. of helix alpha1, modelling, overview
dimer
-
1 * 83000 + 1 * 71000, SDS-PAGE
dimer
alpha,beta 1 * 73000 + 1 * 70000, SDS-PAGE, soluble form
dimer
-
1 * 72000 + 1 * 80000, SDS-PAGE
dimer
alpha1,beta1, 0.9 equivalents of heme per sGC subunit
dimer
-
alpha1beta1, heme moiety is localized in beta1 subunit
dimer
-
1 * 77000, alpha-subunit, + 1 * 70000, beta-subunit, SDS-PAGE
dimer
a heterodimer consisting of an alpha- and beta-subunit, the secondary structural model of the sGC beta2 5'-UTR predicts a Y-type pseudoknot
dimer
soluble guanylyl cyclase is an obligatory heterodimeric protein composed of one alpha- and one beta-subunit
dimer
-
the enzyme is active as a heterodimer of alpha and beta subunits, but probably requires additional components for activity
dimer
-
1 * 79400 + 1 * 74000
dimer
-
1 * 82000 + 1 * 70000, SDS-PAGE
dimer
-
the enzyme is active as a heterodimer of alpha and beta subunits, but probably requires additional components for activity
heterodimer
-
-
heterodimer
-
alphabeta heterodimer, the sGCalpha1 subunit harbors an essential part of the catalytic domain
heterodimer
-
deletion mutants, bimolecular fluorescence complementation
heterodimer
the enzyme is a heterodimer composed of alpha1 and beta1 subunits
heterodimer
1 * 38500 + 1 * 19500, gel filtration, homodimers of sGC have also been observed but are not functionally active
heterodimer
-
1 * 78600 + 1 * 70400, calculated from amino acid sequence
heterodimer
-
1 * 80000 + 1 * 72000, SDS-PAGE
homodimer
-
2 x 68000, SDS-PAGE
homodimer
-
functional enzyme form of atrial natriuretic factor receptor guanylate cyclases
monomer
-
-
additional information
structural domains include the extracellular domain, kinase-like domain, and guanylate cyclase domain, molecular modelling, overview
additional information
-
structural domains include the extracellular domain, kinase-like domain, and guanylate cyclase domain, molecular modelling, overview
additional information
domain structure of a receptor guanylyl cyclase CsGC-YO1, overview
additional information
-
domain structure of a receptor guanylyl cyclase CsGC-YO1, overview
additional information
domain structure of the receptor guanylyl cyclase CsGC-YO1, CsGC-YO1 contains and extracellular domain, overview
additional information
-
domain structure of the receptor guanylyl cyclase CsGC-YO1, CsGC-YO1 contains and extracellular domain, overview
additional information
-
the dimerization region of beta1 extends over 205 residues of its regulatory and central domains and two discontinous sites of 41 and 30 residues, respectively, facilitate binding of beta1 to the alpha1 subunit of soluble guanylyl cyclase
additional information
-
isozyme GC-A has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-A has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-A has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-A has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-A has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
-
isozyme GC-B has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-B has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-B has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-B has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-B has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
-
isozyme GC-C has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-C has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-C has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-C has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-C has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
-
isozyme GC-F has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-F has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-F has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-F has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozyme GC-F has a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
-
isozymes GC-D, GC-E, to GC-G share a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozymes GC-D, GC-E, to GC-G share a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozymes GC-D, GC-E, to GC-G share a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozymes GC-D, GC-E, to GC-G share a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
isozymes GC-D, GC-E, to GC-G share a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
-
the C-terminal portion of RetGC1 contains its regulatory and catalytic domains
additional information
structure molecular modeling of N-terminal domains of GC alpha1 and beta1 subunits
additional information
-
structure molecular modeling of N-terminal domains of GC alpha1 and beta1 subunits
additional information
-
isozymes GC-A to GC-G share a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic guanylate cyclase region, structure and functions of membrane guanylate cyclase isozymes, overview
additional information
-
structure molecular modeling, overview
additional information
-
structural domains include the extracellular domain, kinase-like domain, and guanylate cyclase domain, molecular modelling, overview
additional information
-
each of the catalytic domains alphacat and betacat (expressed in Escherichia coli), form homodimers. Heterodimers are formed when alphacat and betacat are combined
additional information
homology structure modeling of the extracellular domain of GC-C, GC-C structure analysis by NMR and fluorescence emission spectroscopy, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
C122A
-
site-directed mutagenesis of the aldosterone modification site, the mutant is insensitive to inhibition by aldosterone or H2O2
I145Y
-
substitution in the full-length beta-subunit of the sGC heterodimer, does not produce an oxygen-binding enzyme, but impedes the association of NO and destabilizes the NO-heme complex. The tyrosine in the distal heme pocket impedes both the binding and dissociation of the CO ligand. Mutation does not affect stimulatory effect of manganese ion on the activity of the enzyme, thus function of the catalytic domain is not directly affected
Y140L
-
yields a protein that no longer binds O2, but still binds NO. Introduction of a tyrosine residue anywhere in the distal pocket that is able to reach an iron-bound O2 is key in stabilization of the FeII-O2 complex, rescuing the mutant
D100N/D102G
-
the mutant shows altered binding of guanylyl cyclase activating protein 1 compared to the wild-type enzyme
D530A
-
mutation in alpha subunit. Protein levels of the catalytically inactive, non-nucleotide binding mutant a1/b1 are not affected by activator drugs
DELTAN364
-
alpha1 DELTAN364 deletion mutant shows a complete loss of sensitivity towards NO or 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and a slight decrease in basal sGC activity
E75Q/E111Q/E155Q
-
the mutant shows altered binding of guanylyl cyclase activating protein 1 compared to the wild-type enzyme
G959A
missense mutation, mutant binds C-type natriuretic peptide on the surface of cells but fails to synthesize cGMP in membrane guanylate cyclase assays. Mutant protein is dephosphorylated and incompletely glycosylated
H105C
-
heme-deficient mutant, 70 times higher basal sGC activity than wild-type, basal activity is not affected by NO, heme reconstituted mutant regains No activation
I734T
substitution in the kinase homology domain linked to Leber congenital amaurosis, prevents binding of both GCAP1-GFP and GCAP2-GFP
L658F
missense mutation, mutant binds C-type natriuretic peptide on the surface of cells but fails to synthesize cGMP in membrane guanylate cyclase assays. Mutant protein is dephosphorylated and incompletely glycosylated
R776W
missense mutation, mutant binds C-type natriuretic peptide on the surface of cells but fails to synthesize cGMP in membrane guanylate cyclase assays. Mutant protein is dephosphorylated and incompletely glycosylated
S473A
mutation of potential phosphorylation site, reduces vmax value by 13-55%
S473E
mutation of potential phosphorylation site, reduces vmax value by 13-55%
S473E/S497E/T500E/S502E/S506E/S510E/T513E
2fold increase of Km value compared to wild-type
S487A
mutation of potential phosphorylation site, reduces vmax value by 13-55%
S487E
mutation of potential phosphorylation site, reduces vmax value by 13-55%
S497A
mutation of potential phosphorylation site, mutation increases Km value about 4fold
S497E
mutation of potential phosphorylation site, reduces vmax value by 13-55%
S497E/T500E/S502E/S506E/S510E/T513E
mutations in potential phosphorylation sites, about 20% of the activity of phosphorylated wild-type
S502A
mutation of potential phosphorylation site, reduces vmax value by 13-55%
S502E
mutation of potential phosphorylation site, reduces vmax value by 13-55%
S506A
mutation of potential phosphorylation site, reduces vmax value by 13-55%
S506E
mutation of potential phosphorylation site, reduces vmax value by 13-55%
S510A
mutation of potential phosphorylation site, reduces vmax value by 13-55%
S510E
mutation of potential phosphorylation site, reduces vmax value by 13-55%
T500A
mutation of potential phosphorylation site, reduces vmax value by 13-55%
T500E
mutation of potential phosphorylation site, reduces vmax value by 13-55%
T513A
mutation of potential phosphorylation site, reduces vmax value by 13-55%
T513E
mutation of potential phosphorylation site, reduces vmax value by 13-55%
W708R
substitution in the kinase homology domain linked to Leber congenital amaurosis, prevents binding of both GCAP1-GFP and GCAP2-GFP
Y708C
missense mutation, mutant binds C-type natriuretic peptide on the surface of cells but fails to synthesize cGMP in membrane guanylate cyclase assays. Mutant protein is dephosphorylated and incompletely glycosylated
F142Y
-
L2 H-NOX mutant, shift of the equilibrium of the FeII-NO complex at 20°C exclusively to the 6-coordinate complex
alpha1L211A
site-directed mutagenesis of the alpha1 subunit
alpha1Y223A
site-directed mutagenesis
H105F
-
the enzyme of heme-free alpha1-subunit/H105F beta1-subunit sGC mutant is not activated by sodium nitroprusside, but by HMR-1766, 1H-[1,2,4]oxidazolol[4,3a]quinoxalin-1-one does not potentiate the activating effect of HMR-1766 in mutant cells, while it does in wild-type cells, binding structure of H105F mutant with HMR-1766, overview
W669A
-
the mutant is only slightly responsive to the ATP/ANF signal, at about 29% compared to the wild-type enzyme
W669F
-
the mutant responds to the ANF/ATP signal like the wild-type ANF-RGC
W669L
-
the mutant is only slightly responsive to the ATP/ANF signal, at about 29% compared to the wild-type enzyme
K237E/D306K/T308G
-
isoform PAC2, engineering of photoactivated adenylyl cyclase to photoactivated guanylyl cyclase, via mutagenesis of the substrate binding-specific residues in cyclase homology domain. The mutant shows typical BLUF photoreceptor properties
K332E/D400K/T402G
-
isoform PAC3, engineering of photoactivated adenylyl cyclase to photoactivated guanylyl cyclase, via mutagenesis of the substrate binding-specific residues in cyclase homology domain. The mutant shows typical BLUF photoreceptor properties
C238S
-
no change in cGMP production
C243S
-
no change in cGMP production
C594D
-
no 1-benzyl-3-(hydroxymethyl-2-furyl)indazole activation, no synergy with NO
C594D/E525K
-
loss of activity
C594Y
-
reduced level of NO and 1-benzyl-3-(hydroxymethyl-2-furyl)indazole activation
D102A
-
the mutant shows 70% of wild type activity
D102E
-
the mutant shows 32% of wild type activity
D102N
-
the mutant shows 20.5% of wild type activity
E138A
the mutant is less responsive to nitric oxide in comparison to the wild type enzyme
E525K/C594D
-
mutation in alpha subunit, mutant does not show a non-competitive mechanism with Mg2+GTPgammaS and Mg2+ATPgammaS that is observed with wild-type enzyme
F120A
-
the mutant shows 73% of wild type activity
G114A
the mutant has characteristics similar to the wild type enzyme
I111A
the mutant has a decreased basal activity and is less responsive to activators in comparison to the wild type enzyme
I41A
the mutant is strongly activated by YC-1, nitric oxide and to a lesser extent by protoporphyrin IX
M537N
-
high level of 1-benzyl-3-(hydroxymethyl-2-furyl)indazole activation
R40A
the mutation results in a drastic decrease not only in basal activity but also in stimulated activity in response to protoporphyrin IX, YC-1, nitric oxide
S64A
-
an alpha1/beta1 sGC mutant, shows resistance to phosphorylation by the cGMP-dependent protein kinase
S64D
-
an alpha1/beta1 sGC mutant, is less activated by NO in comparison to the wild-type enzyme
E497K/C566D
mutations within the nucleotide binding site generates rhodopsin-adenylyl cyclase
E497K/C566D
-
mutations within the nucleotide binding site generates rhodopsin-adenylyl cyclase
-
D477A
-
reduced level of NO and 1-benzyl-3-(hydroxymethyl-2-furyl)indazole activation
D477A
-
mutation in beta subunit, mutant does not show a non-competitive mechanism with Mg2+GTPgammaS and Mg2+ATPgammaS that is observed with wild-type enzyme
K196E/D264K/T266G
-
engineering of photoactivated adenylyl cyclase to photoactivated guanylyl cyclase, via mutagenesis of the substrate binding-specific residues in cyclase homology domain. The mutant shows typical BLUF photoreceptor properties
K196E/D264K/T266G
-
engineering of photoactivated adenylyl cyclase to photoactivated guanylyl cyclase, via mutagenesis of the substrate binding-specific residues in cyclase homology domain. The mutant shows typical BLUF photoreceptor properties
-
additional information
-
deletion of the gene coding for the atypical sGC, gcy-35, results in loss of O2-dependent behavioral preference for 5-12% oxygen in worms, also prevents the expression of a feeding behavioral polymorphism
additional information
-
double mutants for gcy genes show defects in thermotaxis, triple mutants for the gcy genes show severe defects in thermotaxis but respond normally to odorants and NaCl, abnormal phenotype of the gcy triple mutants can be rescued by expression of any one of the three GCY proteins, gcy-8, gcy-18, and gcy-23. In the AFD neurons no defects in thermotaxis behaviors in gcy single mutants
additional information
double mutants for gcy genes show defects in thermotaxis, triple mutants for the gcy genes show severe defects in thermotaxis but respond normally to odorants and NaCl, abnormal phenotype of the gcy triple mutants can be rescued by expression of any one of the three GCY proteins, gcy-8, gcy-18, and gcy-23. In the AFD neurons no defects in thermotaxis behaviors in gcy single mutants
additional information
-
misexpression of a Gal4-VP16 induced gene or deletion of gene gucy2F leads to multiple defects including morphological defects and loss of forebrain neurons. Screening for gain-of-function mutants, method development for use in large-scale genetic screens in a vertebrate model organism, evaluation, overview. Increased cGMP in embryos with gucy2F overexpression
additional information
mutant sGCdeltacat with point mutation introduced in the catalytic site, loses catalytic activity, shows poor myosin localization at the back, but excellent localization of the sGC protein at the leading edge, where it enhances the probability that a new pseudopod is made in proximity to previous pseudopodia, resulting in a decrease of the degree of turning. Mutant sGCdeltaN with deletion of the N-terminal 877 amino acids, exhibits excellent cGMP formation and myosin localization in the back of the cell, but exhibits poor orientation at the leading edge
additional information
generation of an isozyme Gyc-89Da deficient mutant, reduced levels of cGMP in Gyc-89Da neurons have no effect on larval ecdysis or eclosion, but isozyme expression is necessary early in adult development to prevent eclosion, phenotype, overview
additional information
generation of an isozyme Gyc-89Da deficient mutant, reduced levels of cGMP in Gyc-89Da neurons have no effect on larval ecdysis or eclosion, but isozyme expression is necessary early in adult development to prevent eclosion, phenotype, overview
additional information
-
generation of an isozyme Gyc-89Da deficient mutant, reduced levels of cGMP in Gyc-89Da neurons have no effect on larval ecdysis or eclosion, but isozyme expression is necessary early in adult development to prevent eclosion, phenotype, overview
additional information
generation of an isozyme Gyc-89Db deficient mutant, reduced levels of cGMP in Gyc-89Db neurons have no effect on larval ecdysis or eclosion, but isozyme expression is necessary early in adult development to prevent eclosion, phenotype, overview
additional information
generation of an isozyme Gyc-89Db deficient mutant, reduced levels of cGMP in Gyc-89Db neurons have no effect on larval ecdysis or eclosion, but isozyme expression is necessary early in adult development to prevent eclosion, phenotype, overview
additional information
-
generation of an isozyme Gyc-89Db deficient mutant, reduced levels of cGMP in Gyc-89Db neurons have no effect on larval ecdysis or eclosion, but isozyme expression is necessary early in adult development to prevent eclosion, phenotype, overview
additional information
-
identification of CT and GA polymorphisms in the 5'-flanking region and the promoter region that acts synergistically to affect the GC-A promoter, transcription activity of genotypes, overview
additional information
-
the depletion of sGC by RNA interference fails to prevent Y-27632- and staurosporine-induced neurite outgrowth
additional information
deletion of a residues Tyr1016-Ser1103 fragment in RetGC1 does not block GCAP2 binding to the cyclase
additional information
-
endothelial NO synthase and natriuretic peptide receptor-A knockout mice, sodium nitroprusside and atrial natriuretic peptide produce enhanced dose-dependent reductions in mean arterial blood pressure in endothelial NO synthase knockout mice. In natriuretic peptide receptor-A knockout mice, sodium nitroprusside produces a dose-dependent reduction in mean arterial blood pressure that is significantly higher than that in wild-type mice. Responsiveness to the cAMP-dependent vasodilator epoprostenol is similar in wild-type, endothelial NO synthase and natriuretic peptide receptor-A knockout animals. Atrial natriuretic peptide causes vasodilatation of the forearm resistance vasculature that is significantly higher in individuals lacking endothelium-derived NO
additional information
-
GC1-/-, GC2-/- and GC1/GC2 double knock-out mice, GC1 expression level is maintained in GC2-/- retina and GC2 expression level is maintained in GC1-/- retina. Deletion of GC1 and GC2 renders rod and cone photoreceptors nonfunctional and unstable. In the rod outer segments of guanylate cyclase double knock-out mice, guanylate cyclase-activating proteins 1 and 2, and cyclic GMP phosphodiesterase are undetectable, although rhodopsin and transducin alpha-subunit are mostly unaffected. Outer segment membranes of GC1-/- and GC double knock-out cones are destabilized and devoid of cone transducin (alpha- and gamma-subunits), cone phosphodiesterase, and G protein-coupled receptor kinase 1, whereas cone pigments are present at reduced levels. Down-regulated proteins show normal RNA transcript levels, indicating that down-regulation is posttranslational
additional information
-
basal cGMP levels are lower in sGCalpha1 knockout strips but NO still significantly increases cGMP levels versus basal. In conclusion, in the absence of sGCalpha1beta1, exogenous NO is able to partially act through sGCalpha2beta1, comparison of the soluble guanylate cyclase (sGC) isoforms ?1?1 and ?2?1, and of wild-type with sGCalpha1 knockout mice in the relaxation of distal colon by exogenous NO and by NANC nerve stimulation, overview
additional information
-
construction and phenotype of sGCalpha1 KO mice, expression levels of sGC subunits are altered in the mutant compared to the wild-type mice, the KO mice show reduced enzyme activation and induced muscle relaxation by CO, overview
additional information
-
construction of a deletion mutant of ANF-RGC lacking the 669WTAPELL675 motif
additional information
construction of a mutant GC-ADELTALys314-Gln330 and transfection into HEK-293 cells leading to complete inhibition of binding of atrial natriuretic peptide and atrial natriuretic peptide-induced cyclic GMP formation, overview. Alternative splicing does not affect membrane localization of GC-A, overview
additional information
construction of a truncated GCC 1-430 construct, GCC ECD, containing the extracellular ligand-binding domain and a C-terminus His6-tag in in colorectal cancer cells using a viral vector, overview
additional information
-
construction of a truncated GCC 1-430 construct, GCC ECD, containing the extracellular ligand-binding domain and a C-terminus His6-tag in in colorectal cancer cells using a viral vector, overview
additional information
-
construction of GC-A knockout mice that show significant chronic hypervolemic hypertension, phenotype, overview
additional information
-
construction of isozyme sGCalpha1-deficient mice, in contrast to wild-type mice, the neurologic and myocardial functions are reduced in cardiac arrest and cardiopulmonary resuscitation, CPR, the detrimental effects are associated with enhanced inflammation of heart and liver, and increased cell death in heart, liver, and brain, which can be prevented by overexpression of NO synthase 3, overview
additional information
-
construction of knockout mice
additional information
-
construction of mice deficient in one of the two isozymes NO-GC1 and NO-GC2 or in both, phenotypes, overview
additional information
-
GC-C knckout in intestinal epithelial cells increases apoptosis following radiation-injury, supplementation with cGMP ameliorates radiation-induced apoptosis, overview
additional information
generation of a mutant mouse with a targeted disruption of the GC-G gene Gucy2g, which shows no histologic abnormalities at baseline, but after I/R injury, elevations in serum creatinine and urea are attenuated in GC-G knockout mice compared with wild-type controls, and this correlated with less tubular disruption, less tubular cell apoptosis, and less caspase-3 activation, phenotype, overview. Direct transfer of a GC-G expression plasmid to the kidneys of GC-G-deficient mice results in a dramatically higher mortality after renal I/R injury
additional information
-
generation of a mutant mouse with a targeted disruption of the GC-G gene Gucy2g, which shows no histologic abnormalities at baseline, but after I/R injury, elevations in serum creatinine and urea are attenuated in GC-G knockout mice compared with wild-type controls, and this correlated with less tubular disruption, less tubular cell apoptosis, and less caspase-3 activation, phenotype, overview. Direct transfer of a GC-G expression plasmid to the kidneys of GC-G-deficient mice results in a dramatically higher mortality after renal I/R injury
additional information
-
generation of sGCalpha1 subunit KO mice, that show abolished muscle relaxation after electric field stimulation more pronounced in female than in male KO mice
additional information
-
mice deficient in isozyme GC-A show marked cardiac hypertrophy and fibrosis, which can be inhibited by both genetic and pharmacological blockade of type 1 angiotensin II receptors. The mutant mice show increased expression of atrial and brain natriuretic peptides, and increased systemic blood pressure and heart weight to body weight ratios compared to the wild-type mice, overview
additional information
-
mouse line lacking retGC-1, GCE null, light-induced transducin redistribution occurs faster in mice lacking ret-GC1, phenotype, overview
additional information
-
nociceptive behavior of mice deficient in NO-sensitive guanylyl cyclase, GC-KO mice fail to develop pain sensitization induced by intrathecal administration of drugs releasing NO or carbon monoxide, NO-, CO-, and cGMP-induced pain behavior in GC-KO mice, overview
additional information
-
GC-C knckout in intestinal epithelial cells increases apoptosis following radiation-injury, supplementation with cGMP ameliorates radiation-induced apoptosis, overview
-
additional information
-
construction of a truncated GCC 1-430 construct, GCC ECD, containing the extracellular ligand-binding domain and a C-terminus His6-tag in in colorectal cancer cells using a viral vector, overview
-
additional information
-
GC1-/-, GC2-/- and GC1/GC2 double knock-out mice, GC1 expression level is maintained in GC2-/- retina and GC2 expression level is maintained in GC1-/- retina. Deletion of GC1 and GC2 renders rod and cone photoreceptors nonfunctional and unstable. In the rod outer segments of guanylate cyclase double knock-out mice, guanylate cyclase-activating proteins 1 and 2, and cyclic GMP phosphodiesterase are undetectable, although rhodopsin and transducin alpha-subunit are mostly unaffected. Outer segment membranes of GC1-/- and GC double knock-out cones are destabilized and devoid of cone transducin (alpha- and gamma-subunits), cone phosphodiesterase, and G protein-coupled receptor kinase 1, whereas cone pigments are present at reduced levels. Down-regulated proteins show normal RNA transcript levels, indicating that down-regulation is posttranslational
-
additional information
-
endothelial NO synthase and natriuretic peptide receptor-A knockout mice, sodium nitroprusside and atrial natriuretic peptide produce enhanced dose-dependent reductions in mean arterial blood pressure in endothelial NO synthase knockout mice. In natriuretic peptide receptor-A knockout mice, sodium nitroprusside produces a dose-dependent reduction in mean arterial blood pressure that is significantly higher than that in wild-type mice. Responsiveness to the cAMP-dependent vasodilator epoprostenol is similar in wild-type, endothelial NO synthase and natriuretic peptide receptor-A knockout animals. Atrial natriuretic peptide causes vasodilatation of the forearm resistance vasculature that is significantly higher in individuals lacking endothelium-derived NO
-
additional information
-
alpha1-sGC and beta1-sGC deletion mutants, coexpression of alpha1-YNV deletion mutants with wild-type-beta1-YCV as well as beta1-YCV deletion mutants with wild-type-beta1-YNV-sGC results in functional heterodimerization of both sGC subunits in the cytosol of the cell
additional information
-
GCC lacking the amino acids from the conserved 63 amino acid span, localized in an unpolarized manner at both the apical and basolateral membranes, GCC protein lacking 32 or 52 amino acids from the COOH terminus, both mutations have no effect on the apical localization of GCC
additional information
-
ONE-GCdeltaext mutant, deleted extracellular domain of ONE-GC, basal guanylate cyclase activity almost identical to that of wild-type, deletion of the extracellular domain has no effect on the tertiary structure of the protein, cannot be stimulated by uroguanylin. Tm bound mutant and soluble cat mutant, both have intrinsic catalytic activity, mutations have not effect on their tertiary structures
additional information
-
construction of heme domain mutant comprising residues beta1(1-194) or beta2(1-217)
additional information
recombinant miniGC-C, comprising the exracellular enzyme domain, binds the heat-stable enterotoxin STp-(5-17) with high affinity, ligand binding and structure analysis, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
beta1 (residues 1-194) and beta2 (residues 1-217) homodimers expressed in Escherichia coli
-
by baculovirus expression system
-
catalytic domains (alphacat and betacat) of alpha1beta1 soluble guanylate cyclase are expressed in Escherichia coli
-
cloning of isozyme GC-A, DNA and amino acid sequence determination, analysis, and quantitative expression analysis, expression of FLAG-tagged or HA-tagged wild-type GC-A and of mutant GC-ADELTALys314-Gln330 and in HEK-293 cells
construction of a fluorescent alpha1/beta1-sGC heterodimer by fusion of the N-terminal YFP fragment and the C-terminal fragment to the N terminus and the C terminus of the alpha1- and beta1-subunit, respectively. Generated fusion proteins, wild-type and deletion mutants transiently expressed in a cGMP reporter cell line based on a Chinese hamster ovary cell line stably transfected with the cyclic nucleotide gated olfactory CNG2A-channel and cytosolic aequorin
-
construction of multiple N- and C-terminal deletion variants and cotransfecting them with full-length alpha1 subunit into COS cells
-
COS-7 cells transfected with the wild-type ONE-GC cDNA or its deletion mutants, ONE-GC mutants into pET30aLIC vector, expressed in Escherichia coli BL21-Codon-Plus-RIL
-
enzyme expression in heart tissue and heterogeneous expression patterns of NO-related regulatory enzyme systems, overview
expressed in Escherichia coli
-
expressed in Escherichia coli BL21 (DE3) as a fusion protein with an N-terminal polyhistidine tag after subcloning into bacterial expression vector pET16b
expressed in Escherichia coli BL21 Star (pLysS) cells
-
expressed in Escherichia coli BL21(DE3) cells
expressed in Escherichia coli BL21(DE3) CodonPlus cells
-
expressed in Escherichia coli BL21(DE3)-R3 cells
expressed in HEK-293T cells
-
expressed in Sf21 insect cells
-
expressed in Sf9 insect cells
expression analysis of enzyme subunits during the estrous cycle overview
-
expression analysis of sGC subunits in pulmonary artery tissue from healthy and hypertensive lungs
expression in CHO cells in a reporter-coupled system, overview
-
expression in COS-7 cells
-
expression in Escherichia coli
expression in HEK-293 cell
expression in in HEK-293T cells
-
expression in Sf9 insect cells
-
expression of a Trx-tagged miniGC-C, comprising the extracellular domain, in Escherichia coli strain AD494(DE3) using expression vector pET-32a
expression of alpha1 and beta1 subunits and mutant enzyme in COSm6 and A7r5 smooth muscle cells
-
expression of alpha1 and beta1 subunits in Sf9 insect cells
-
expression of alpha1 and beta1 subunits of sGC in Sf9 insect cells
expression of His-tagged heterodimeric full-length and N-terminal fragments of Manduca sexta sGC in Escherichia coli strains BL21(DE3)
expression of His-tagged soluble guanylate cyclase in Spodoptera frugiperda SF9 cells using the baculovirus transfection method
-
expression of His-tagged truncated cyclase domain in Escherichia coli C41. The mutant enzyme E497K/C566D is expressed the N-terminal YFP-tagged constructs in oocytes
expression of isoform alpha2,beta1 in Sf9 cells
expression of sGC in BE2 human neuroblastoma cell line and in Spodoptera frugiperda SF9 cells, quantitative expression analysis of sGC splice variants, overview
expression of sGC in insect cells
-
expression of sGC in Sf9 insect cells and COS-7 cells
-
expression of sGCalpha and sGCbeta subunit in Sf1 insect cells
-
expression of the heme-free alpha1-subunit/H105F beta1-subunit sGC mutant in COS-7 cells
-
expression of the His6-tagged truncated enzyme mutant in CT26 mouse colon cancer cells, subclining in 293T cells
expression of the intracellular domain of GCC in Sf21 insect cells
-
expression of wild-type alpha1beta2 sGC enzyme in Spodoptera frugiperda Sf9 cells, and of heme domain mutants in Escherichia coli
-
expression of wild-type and C122A mutant enzymes in COS-7 cells
-
expression of wild-type and mutant enzymes in COS-7 cells
-
expression of wild-type and mutant in Sf9 cells
-
expression of wild-type GFP-tagged RetGC1 and commercially available dsRet-tagged RetGC1 in HEK-293 cells, co-expression with either fluorescently tagged or non-tagged guanylyl cyclase activating protein 1, with inactivated metal binding in individual EF-hands, in cell membranes. The uniform cellular distribution of GCAP1, also in the nucleus, drastically changes when the cells express both GCAP1-GFP and RetGC1, GCAP1 is then depleted from the nuclei and only observed in the cytoplasm of the cells, overview
-
full-length genomic gcy gene sequence fused to the GFP gene and injected into wild-type animals
functional chimeras between the catalytic domains of the mycobacterial adenylyl cyclase Rv1625c and a Paramecium guanylyl cyclase
-
functional transient expression of GC-D HEK-293T cell membranes, expression of His-tagged intracellular cyclase domain of GC-D consisting of GC-D residues 850-1110 in insect HiFive cells by using the baculovirus expression system
-
GC-A gene, genotyping of hypertensive and normotensive Japanese, association of CT dinucleotide repeat polymorphism in the 5'-flanking region of the GC-A gene with essential hypertension in the Japanese, overview
-
gene CsGC-YO1, DNA and amino acid sequence determination and analysis, quantitative expression by real-time PCR assay, expression of the extracellular domain of CsGC-YO1 in Escherichia coli
gene CsGC-YO1, DNA and amino acid sequence determination and analysis, tissue expression analysis, expression of the extracellular domain of CsGC-YO1 in Escherichia coli
gene CYG12 encodes the soluble isozyme
gene encoding isozyme Gyc-89Da, expression analysis and promoter analysis, expression in Saccharomces cerevisiae
gene encoding isozyme Gyc-89Db, expression analysis and promoter analysis, expression in Saccharomces cerevisiae
gene gc1, DNA and amino acid sequence determination, RET-GC1 expression analysis in retinal tissue, overview
gene gc2, DNA and amino acid sequence determination, RET-GC2 expression analysis in retinal tissue, overview
gene gc3, DNA and amino acid sequence determination, RET-GC3 expression analysis in retinal tissue, overview
genes gucy1a3 and gucy2F, DNA and amino acid sequence determination and analysis, and expression analysis. Overexpression of wild-type and mutant enzymes in zebrafish embryos
-
Gyc-88E(1-597) expressed in S2 cells as a polyoma-tagged construct under the control of the metallothionein promoter
-
into the pCRHT7 TOPOH-NT vector and expressed in Escherichia coli BL21 (DE3) pLysS cells
-
isolation of two mRNA species for sGC beta2 with dissimilar 5'-untranslated regions from human kidney, translational mechanism of the sGC beta2-subunit, overview. Insertion of these regions between the two luciferase genes of a bicistronic vector and transfection into HeLa cells, both sGC beta2 leaders have internal ribosome entry site, IRES, activity in a cell-type dependent manner. The sGC beta2 IRES is functional in a wide range of cell lines, e.g. HeLa cells, Hep-G2 cells, COS-7 cells, and CCL-185 cells
isozymes GC-D, GC-E, to GC-G
MDCK cell lines expressing HA-tagged GCC or HA-tagged GCC lacking the amino acids from the conserved 63 amino acid span
-
membrane-bound guanylate cyclase, phylogenetic analysis
N-terminal heme-binding regions of subunit beta1 from soluble guanylate cyclase are generated by subcloning specific constructs into the Escherichia coli expression vector pET-20b. The shortest region that is subcloned, has heme-bound, and is expressed well is beta1(1-194)
-
overexpression in a baculovirus/Sf9 system
quantitative analysis of promoter activity and determination of transcriptional start sites within the 5'-flanking region of alpha1 and beta1 sGC using transiently transfected luciferase reporter constructs, expression in human aortic smooth muscle cells and in COS-7 cells
-
sGC beta1 cDNA inserted between the NotI and XbaI sites of the plasmid pFastBac1, H6sGC alpha1 gene inserted between the NotI and XbaI sites of pFastBac1, expression in Sf9 cells
-
the beta1 subunit of soluble guanylyl cyclase is expressed in Escherichia coli BL21 (DE3) pLysS cells
the sGCalpha1 gene encodes for an essential part of the catalytic domain. Quantitative expression analysis by RT-PCR and relative levels of alpha1, alpha2, and beta1 subunit mRNA in male KO tissues versus male wild-type tissues
-
transfection of COS-7 cell
transfection of HEK-293T cell
transfection of Sf9 cells
-
transient expression in COS-7 cells
transient expression in COS-7 cells as GST-tagged enzyme, reconstitution of the Galphat-retGC interaction in COS-7 cells, overview
transiently transfected into COS-7 cells
-
wild-type and mutant enzymes expressed in Sf21/baculovirus system
-
wild-type sGC and mutant sGC constructs fused at the C-terminus to GFP and expressed in gc-null cells
enzyme expression in heart tissue and heterogeneous expression patterns of NO-related regulatory enzyme systems, overview
-
enzyme expression in heart tissue and heterogeneous expression patterns of NO-related regulatory enzyme systems, overview
-
expressed in Escherichia coli BL21(DE3) cells
-
expressed in Escherichia coli BL21(DE3) cells
expressed in Escherichia coli BL21(DE3) cells
expressed in Sf9 insect cells
-
expressed in Sf9 insect cells
-
expression analysis of sGC subunits in pulmonary artery tissue from healthy and hypertensive lungs
-
expression analysis of sGC subunits in pulmonary artery tissue from healthy and hypertensive lungs
-
expression analysis of sGC subunits in pulmonary artery tissue from healthy and hypertensive lungs
-
expression in Escherichia coli
-
expression in Escherichia coli
-
expression of His-tagged truncated cyclase domain in Escherichia coli C41. The mutant enzyme E497K/C566D is expressed the N-terminal YFP-tagged constructs in oocytes
-
expression of His-tagged truncated cyclase domain in Escherichia coli C41. The mutant enzyme E497K/C566D is expressed the N-terminal YFP-tagged constructs in oocytes
into pET-20b vector
-
membrane-bound guanylate cyclase, phylogenetic analysis
-
membrane-bound guanylate cyclase, phylogenetic analysis
membrane-bound guanylate cyclase, phylogenetic analysis
-
overexpression in a baculovirus/Sf9 system
-
overexpression in a baculovirus/Sf9 system
-
transient expression in COS-7 cells
-
transient expression in COS-7 cells
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
analysis
-
purified sGC can act as detector for NO-like bioactivity generated from nitrite and glycerol trinitrate and for NO released by heart and liver mitochondria
diagnostics
-
CT and GA polymorphisms in the 5'-flanking region of the GC-A gene might be useful as susceptibility marker for hypertension
drug development
-
the soluble guanylate cyclase is a target for compounds used in therapy of heart failure, e.g. nitric oxide-independent, soluble guanylate cyclase activator cinaciguat, BAY 58-2667, that induces vasodilation preferentially in diseased vessels, overview
medicine
-
antiproliferative mechanisms induced by GCC ligands and exisulind negatively interact in colon cancer cells
medicine
-
crosstalk occurs between the NO-sGC and atrial natriuretic peptide-pGC pathways to regulate cGMP-dependent vasodilatation in vivo
medicine
-
crosstalk occurs between the NO-sGC and atrial natriuretic peptide-pGC pathways to regulate cGMP-dependent vasodilatation in vivo
medicine
-
different roles of the natriuretic peptide and NO systems. In acute heart failure, the natriuretic peptide system plays a role in maintaining sodium excretion and glomerular filtration rate, while the function of the NO system is in the maintenance of renal blood flow. These two cGMP activating systems function through two distinct GC enzymes, playing a key role in maintaining renal function in acute heart failure
medicine
guanylyl cyclase activity is related to intracellular Ca2+ mobilization and this Ca2+-cGMP cross-talk may in turn be associated with parasite infectivity
medicine
-
limited species differences in sGC subunit distribution of primates and rodents. NO-cGMP signaling pathway may be involved in important brain functions such as memory formation, sensory processing, and behavior
medicine
-
limited species differences in sGC subunit distribution of primates and rodents. NO-cGMP signaling pathway may be involved in important brain functions such as memory formation, sensory processing, and behavior
medicine
-
NO-sGC pathway in the subnucleus caudalis is involved in mediating orofacial muscle hypersensitivity under acute inflammatory condition
medicine
-
sensitivity of guanylyl cyclase heme nitrosylation as well as oxygen-dependent NO consumption may be particularly adapted to direct itinerant endothelial cells into hypoxic tissues in the setting of inflammation, wound healing, and cancer
medicine
-
targeting soluble guanylate cyclase with BAY 41-2272 may represent a therapy in the management of voiding disturbances associated with impaired NO-cGMP signaling
medicine
-
the enzyme stimulation, e.g. by riociguat, is a strategy in treatment of pulmonary hypertension, moderate-to-severe phenotype, associated with impaired production of the vasodilator nitric oxide, study of safety, tolerability and efficacy in patients
medicine
-
inhibition of sGC is an approach to restore hypoxic pulmonary vasoconstriction during endotoxemia
medicine
-
in red blood cells, an intact soluble guanylate cyclaseC/PDE5/PKG-dependent signaling pathway exists, which remains fully responsive to NO and guanylate cyclase stimulators/activators in patients with endothelial dysfunction
medicine
-
guanylyl cyclase activity is related to intracellular Ca2+ mobilization and this Ca2+-cGMP cross-talk may in turn be associated with parasite infectivity
-
medicine
-
crosstalk occurs between the NO-sGC and atrial natriuretic peptide-pGC pathways to regulate cGMP-dependent vasodilatation in vivo
-
molecular biology
the enzyme is a favorable optogenetic tool for non-invasive, cell-selective, and spatio-temporally precise modulation of cAMP/cGMP with light. The rhodopsin domain from Catenaria is more photostable than that from Blastocladiella, and the signaling state persists longer, both of which are highly desirable traits for optogenetic applications
molecular biology
-
the enzyme is a favorable optogenetic tools for non-invasive, cell-selective, and spatio-temporally precise modulation of cAMP/cGMP with light. The rhodopsin domain from Catenaria is more photostable than that from Blastocladiella, and the signaling state persists longer, both of which are highly desirable traits for optogenetic applications
molecular biology
-
the enzyme is a favorable optogenetic tool for non-invasive, cell-selective, and spatio-temporally precise modulation of cAMP/cGMP with light. The rhodopsin domain from Catenaria is more photostable than that from Blastocladiella, and the signaling state persists longer, both of which are highly desirable traits for optogenetic applications
-
pharmacology
-
activators of sGC may be beneficial in the treatment of a range of diseases including systemic and pulmonary hypertension, heart failure, atherosclerosis, peripheral arterial occlusive disease, thrombosis and renal fibrosis, overview
pharmacology
alternative splicing can regulate endogenous ANP/GC-A signaling, thus, angiotensin II-induced alternative splicing of GC-A may represent a mechanism for reducing the sensitivity to atrial natriuretic peptide
pharmacology
-
sGC is a target for therapeutic intervention in pulmonary arterial hypertension
pharmacology
-
pharmacological approaches do not allow cell specific manipulation of cyclic nucleotides in tissue and lack precision in space and time, limitations that can be overcome using the light-activated enzyme
pharmacology
pharmacological approaches do not allow cell specific manipulation of cyclic nucleotides in tissue and lack precision in space and time, limitations that can be overcome using the light-activated enzyme
pharmacology
-
pharmacological approaches do not allow cell specific manipulation of cyclic nucleotides in tissue and lack precision in space and time, limitations that can be overcome using the light-activated enzyme
-
additional information
-
biochemical properties of Gyc-88E are unique for guanylate cyclases, the enzyme possibly functions as an oxygen sensor
additional information
-
BR1 may belong to a class of guanylate cyclases that contains both a cytosolic kinase and GC domain
additional information
-
bronchial smooth muscle cGMP-, but not cAMP-dependent, relaxant response is developmentally regulated and significantly reduced in the adult rat, correlates with the higher expression of the two isoforms and higher activity of sGC in newborn rat bronchial tissue
additional information
cGMP suppresses pseudopod formation in the back of the cell, whereas the sGC protein refines pseudopod formation at the leading edge
additional information
-
coexistence of homologous and heterologous desensitization of GC-A in the same cell type, these reactions are mediated by different pathways, cross talk between phospholipid and natriuretic peptide signaling
additional information
-
differences in the effects of ATP on signal transduction of GC-coupled natriuretic peptide receptor A between Wistar Kyoto and spontaneously hypertensive rats
additional information
-
GCC is involved in cytosolic apical sorting signals in epithelial cells, apical sorting determinant for GCC is a region of 11 highly conserved amino acids (PTPPTVENQQR) in the COOH terminus, which are essential for the normal polarization of GCC in MDCK cells. This sequence is sufficient to selectively target an unpolarized reporter protein, interleukin-2 receptor alpha-chain, to the apical membrane
additional information
-
intrinsic requirement of guanylate cyclases for stability and/or transport of a set of membrane-associated phototransduction proteins
additional information
-
NO-cGMP pathway modulates the neural circuitry in inner retina, preferentially within the cone pathway
additional information
-
residues H104, Y140, the YxS/TxR motif and missing cysteines Cys78 and Cys214 are conserved in all the insect atypical sGC subunits
additional information
-
residues H104, Y140, the YxS/TxR motif and missing cysteines Cys78 and Cys214 are conserved in all the insect atypical sGC subunits
additional information
-
residues H104, Y140, the YxS/TxR motif and missing cysteines Cys78 and Cys214 are conserved in all the insect atypical sGC subunits
additional information
-
residues H104, Y140, the YxS/TxR motif and missing cysteines Cys78 and Cys214 are conserved in all the insect atypical sGC subunits
additional information
-
residues H104, Y140, the YxS/TxR motif and missing cysteines Cys78 and Cys214 are conserved in all the insect atypical sGC subunits
additional information
-
residues H104, Y140, the YxS/TxR motif and missing cysteines Cys78 and Cys214 are conserved in all the insect atypical sGC subunits
additional information
-
residues H104, Y140, the YxS/TxR motif and missing cysteines Cys78 and Cys214 are conserved in all the insect atypical sGC subunits
additional information
-
residues H104, Y140, the YxS/TxR motif and missing cysteines Cys78 and Cys214 are conserved in all the insect atypical sGC subunits
additional information
-
residues H104, Y140, the YxS/TxR motif and missing cysteines Cys78 and Cys214 are conserved in all the insect atypical sGC subunits. Atypical sGCs can function as O2 sensors and can modulate sensitivity to sweet tastants
additional information
-
segments spanning amino acids alpha1 363-372, alpha1 403-422, alpha1 440-459, beta1 212-222, beta1 304-333, beta1 344-363, and beta1 381-400 within the predicted dimerization region are involved in the process of heterodimerization and therefore in expression of functional sGC
additional information
-
sGC has two NO-regulated activity states
additional information
-
two nucleotide-binding sites with high and low affinity for GMP-CPP, one of the two sites constitutes the substrate site responsible for catalysis. The other site is the pseudosymmetric site, which exclusively serves as the binding site for YC-1 or BAY 41-2272
additional information
-
intrinsic requirement of guanylate cyclases for stability and/or transport of a set of membrane-associated phototransduction proteins
-